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SUMMARY 
 
Varying levels of Rifampicin (RIF) resistance in closely related clinical Mycobacterium tuberculosis 
isolates and in vitro generated mutants question the dogma that non-synonymous single nucleotide 
polymorphisms in the rpoB gene are the only mechanism explaining RIF resistance. This study aimed to 
identify biological mechanisms that define the level of RIF resistance in two closely related clinical M. 
tuberculosis isolates using proteomic, transcriptomic and genomic approaches. Two dimensional 
electrophoresis revealed an increase in the abundance of numerous membrane proteins in response to RIF 
at the critical concentration of 2 g/ml. Fourty-one of these proteins were identified by mass spectrometry 
and could be grouped according to their cellular function (Energy metabolism, degradation, biosynthesis 
of cofactors, metabolic groups and carriers, lipid biosynthesis, central intermediate metabolism, synthesis 
and modification of macromolecules, chaperone/heat shock proteins). The identification of proteins 
responsible for ATP synthesis (atpA and atpH) suggests an ATP requirement to combat the toxic effect of 
RIF.  These proteins are components of the FoF1 ATP synthase an enzyme which is involved in the 
oxidative phosphorylation pathway that generates ATP in the cell.  QRT-PCR confirmed the up 
regulation of the transcription of the atpA and atpH genes in response to RIF, while DNA sequencing 
failed to identify mutations that could define the rate of transcription.  
 
To explain our findings we proposed that RIF induces a toxic response leading to the up regulation of a 
number of genes. The induction of metabolic enzymes, such as the FoF1 ATP synthase provides energy 
to activate ATP dependant mechanisms, including membrane ABC transporters. These ABC transporters 
actively pump RIF out of the cell thereby lowering the intracellular concentration of RIF to below its 
binding concentration with the rpoB protein leading to RIF resistance. Inhibition of efflux by the efflux 
pump inhibitors reserpine and verapamil leads to an accumulation of RIF within the cell and concurrent 
binding of RIF to rpoB, leading to inhibition of transcription and cell death (ongoing research in our 
laboratory). Similarly, we propose that the recently identified diarylquinoline compound (TMC207) 
inhibit ATP synthesis, thereby depleting the energy source necessary for active efflux. This will lead to an 
accumulation of anti-TB drug within the cell and subsequent cell death.  In summary, this study provides 
the first evidence to suggest that the evolution of RIF resistance is a dynamic process involving a cascade 
of adaptive events which leads to a bacterial growth state where hydrophobic compounds are actively 
extruded from the cell. This has important ramifications for the treatment of RIF resistant TB and 
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supports the need for the development of anti-TB drugs that target both efflux and ATP synthesis to 
improve the treatment outcome of MDR-TB and XDR-TB. 
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OPSOMMING 
 
Verskillende vlakke van Rifampisien (RIF) weerstandigheid, in naby verwante Mycobacterium 
tuberculosis kliniese isolate en in vitro mutante, bevraagteken die dogma dat nie-sinonieme 
enkel nukleotied polimorfismes in die rpoB geen die enigste verklaarbare  meganisme vir RIF 
weerstandigheid is. Die doel van hierdie studie was om deur „n proteomiese, transkriptomiese en 
genomiese benadering, biologiese meganismes te identifiseer wat die vlakke van RIF 
weerstandigheid in twee naby verwante kliniese M. tuberculosis isolate bepaal. Twee 
dimensionele elektroferese het gevind dat daar „n verhoging in die hoeveelheid van verskeie 
proteïne is wanneer die isolate aan RIF by die „n kritiese konsentrasie van 2µg/ml blootgestel is. 
Massa spektrometrie het 41 van hierdie proteine geïdentifiseer en die proteïne kan gegroepeer 
word in verskeie sellulêre funksies (Energie metabolism, degradering, biosintese van kofaktore, 
metaboliese groepe en draers, lipied biosintese, sentrale intemediêre metabolisme, sintese en 
modifisering van makromolekules, en “chaperone/heat shock” proteine). Die identifisering van 
proteïne verantwoordlik vir ATP sintese (atpA en atpH) stel voor dat ATP belangrik is om die 
toksiese effek van RIF te ontwyk.  Hierdie proteïne is komponente van die FoF1 ATP sintase 
ensiem wat betrokke is in die oksidatiewe fosforilerings pad en wat lei tot die generering van 
ATP in die sel.  Kwantitatiewe QRT-PCR het bevestig dat hierdie gene, atpA en atpH, 
opgereguleer word nadat die bakterium aan RIF blootgestel is. In teen deel kon DNA volgorde 
bepaling nie mutasies identifiseer wat die verandering in geen transkripsie kon verklaar nie. 
 
Om ons bevindings te verduidelik, stel ons voor dat RIF „n toksiese effek in die sel induseer wat 
lei tot die opregulering van verskeie gene. Die indusering van metaboliese ensieme, soos die 
FoF1 ATP sintase, voorsien energie om ATP afhanklike meganismes, insluitende membraan 
ABC transporters, te aktiveer. Hierdie ABC transporters pomp RIF aktief uit die sel, wat 
daarvolgens die intrasellulêre konsentrasie van RIF verlaag tot „n konsentrasie laer as die 
bindings konsentrasie met die rpoB protein en gevolglik lei tot weerstandigheid. Die 
onderdrukking van membraan pompe wat RIF uit die sel pomp deur middels soos reserpine en 
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verapamil sal aanleiding gee lei tot akkumulering van RIF in die sel. Die verhoogde RIF in die 
sel versoorsaak dat RIF aan die rpoB protein gebind bly sodat dit transkripsie inhibeer, wat dan 
aanleiding gee tot seldood. (voortgesette navorsing in ons laboratorium). Soortgelyk, stel ons 
voor dat die onlangs geïdentifiseerde dairylquinoline verbinding (TMC207) ATP sintese inhibeer 
en daarvolgens die energie bron uitput wat noodsaaklik is vir aktiewe uitpomp van RIF. Dit sal 
aanleiding gee tot die ophoping van RIF in die sel en gevolglik lei tot seldood.  
 
In opsomming, hierdie studie voorsien die eerste bewys wat voorstel dat die evolusie van RIF 
weerstandighied ‟n dinamiese proses is. Dit sluit „n kaskade van aanpasbare gebeurtenisse in wat 
lei tot „n bakteriële groei fase waar hidrofobiese verbindings aktief uit die sel gedryf word.  Dit 
het rampspoedige gevolge vir die behandeling van RIF weerstandige TB en ondersteun die 
noodsaaklikheid om teen-TB middels te ontwikkel wat beide effluks pompe en ATP sintese 
teiken om die uikoms van behandeling vir MDR-TB en XDR-TB te verbeter.   
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CHAPTER 1 
INTRODUCTION 
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1.1. BACKGROUND 
 
South Africa, with a Tuberculosis (TB) incidence of 948/100 000 per annum and 15 914 Multi Drug 
Resistant (MDR) cases reported in 2007, was declared by the WHO as one of the countries with the 
highest burden of TB (16). MDR-TB is defined as Mycobacterium tuberculosis (M. tuberculosis) strains 
resistant to the two most important first-line anti-TB antibiotics, Isoniazid (INH) and Rifampicin (RIF) 
(6). Recently Extreme Drug Resistant (XDR) strains were identified and these are currently widespread 
found in all provinces of South Africa. XDR-TB strains are MDR and in addition are also resistant to any 
Fluoroquinolone and one of the injectable antibiotics, i.e. Kanamycin, Amikacin and Capreomycin (6). 
These two forms of highly drug resistant strains is a major public health concern globally. For the past 4 
decades no new anti-TB drugs have been developed (9). This raises the concern of a future epidemic of 
virtually untreatable TB and the need for the development of new drugs to effectively treat all forms of 
TB (8). 
 
The TB incidence in the Western Cape is an alarming 1005.7/100 000 per annum (3). Approximately 70% 
of the drug resistant epidemic in the Western Cape are driven by 4 strain families: Beijing/W-like (28%), 
Low Copy Clade (LCC) (26%), F11 (12%) and F28 (5%) (11). Recently, outbreaks of MDR clones 
within the Beijing (R220) and LCC (DRF150) families were reported in local communities. Strains 
belonging to the Beijing R220 genotype are characterized by an IS6110 insertion at position 3709536 and 
a -15 inhAC-T promoter mutation (conferring INH resistance). The DRF 150 genoptype is characterized by 
a unique spoligotype and RFLP patterns as well as a dinucleotide mutation at position 315 in the katG 
gene (315gc → ca) (15). These specific strains still transmits successfully, irrespective of the presence of 
characteristic mutations. Therefore it is suggested that these strains have unique properties which aids in 
increased transmissibility and drug tolerance.  
 
RIF is considered to be one of the most important front-line drugs used to treat TB.  RIF targets and 
interacts with the beta subunit of the RNA polymerase, hindering RNA synthesis and therefore killing the 
organism (12). In contrast, resistance to RIF develops through single nucleotide substitutions in the 81bp 
core region called the RIF Resistance Determining Region (RRDR) of the RNA polymerase gene (rpoβ) 
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(13). These nucleotide substitutions result in structural conformational changes in RNA polymerase, 
resulting in defective binding of RIF to RNA polymerase. Resistance to RIF can be considered as a 
marker for Multi Drug Resistance-TB as mono resistance to RIF is rarely seen and is usually 
accompanied by INH resistance (2,4,7). 
 
RIF resistant characteristics of M. tuberculosis have been extensively studied in the laboratory strain, 
H37Rv, and in vitro selected mutants. It is suggested that a direct relationship exist between different 
nsSNP‟s causing drug resistance and the level of drug resistance (14,17). It is possible that each nsSNP in 
the rpoB gene alters the dissociation constant of the mutated rpoB (rpoBmut) RIF complex (Kd
R
) in such 
an manner that this strongly influences the RIF MIC. However, it has been shown that in vitro RIF MIC‟s 
are highly variable at specific rpoB codons when measured among drug-resistant TB clinical isolates 
(1,10). Furthermore, varying RIF MIC‟s among in vitro generated isogenic RIF-resistant clones (with 
identical nsSNP‟s in the rpoB gene) have been reported (5).  However, the mechanism by which a strain 
becomes hyper-resistant to RIF is still not known. 
 
It has been shown that Mycobacteria have adapted to implicate other mechanisms, other than 
chromosomal alterations in anti-TB target genes, to become resistant to anti-TB drugs. These mechanisms 
and its regulation thereof will be discussed in detail in Chapter 2 of this thesis.  
 
1.2. PROBLEM STATEMENT 
Our group (Phd Thesis, Gail E Louw, 2009) observed that RIF MIC‟s varied in genotypically closely 
related clinical isolates which share identical IS6110 genotypes and identical drug resistance causing gene 
mutations. In these isolates, the RIF MIC‟s ranged from 5 to 170 μg/ml in 7H9 liquid media. This 
challenges the dogma that a single nsSNP in the rpoB gene defines the level of RIF resistance. 
Accordingly we suggest that RIF-resistance develops through a stepwise process beginning with an initial 
nsSNP within the rpoB gene, which is followed by either subsequent mutations in other genes or by drug 
induced gene regulation which modulates the intra-cellular concentration of RIF. 
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1.3. HYPOTHESIS 
We hypothesise that M. tuberculosis might develop RIF resistance through other mechanisms and unique 
pathways due to selective pressure under prolonged exposure to RIF and patient non-compliance. The 
combination of nsSNP in the rpoB gene and these unique mechanisms defines the level of RIF and 
enables the organism to become hyper-resistant. 
 
1.4. AIMS 
The aim of this project is to identify mechanisms which define the level of RIF resistance in M. 
tuberculosis. 
 
1.5. EXPERIMENTAL APPROACH 
Proteomic, transcriptomic and genomic methods were used to identify mechanisms which can explain the 
varying levels of RIF resistance in two closely related clinical isolates. 
 
1.6. REFERENCES 
 
 1.  Cummings, M. P. and M. R. Segal. 2004. Few amino acid positions in rpoB are associated with 
most of the rifampin resistance in Mycobacterium tuberculosis. BMC.Bioinformatics. 5:137. 
 2.  Gillespie, S. H. 2002. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and 
molecular perspective. Antimicrob.Agents Chemother. 46:267-274. 
 3.  Health Systems Trust. Department of Health (TB section).  1. 2007.  
Ref Type: Data File 
 4.  Hoek, K. G., N. C. Gey Van Pittius, H. Moolman-Smook, K. Carelse-Tofa, A. Jordaan, G. D. van der 
Spuy, E. Streicher, T. C. Victor, P. D. van Helden, and R. M. Warren. 2008. Fluorometric assay for 
testing rifampin susceptibility of Mycobacterium tuberculosis complex. J.Clin.Microbiol. 46:1369-
1373. 
5 
 
 5.  Huitric, E., J. Werngren, P. Jureen, and S. Hoffner. 2006. Resistance levels and rpoB gene 
mutations among in vitro-selected rifampin-resistant Mycobacterium tuberculosis mutants. 
Antimicrob.Agents Chemother. 50:2860-2862. 
 6.  Jones, K. D., T. Hesketh, and J. Yudkin. 2008. Extensively drug-resistant tuberculosis in sub-
Saharan Africa: an emerging public-health concern. Trans.R.Soc.Trop.Med.Hyg. 102:219-224. 
 7.  Mokrousov, I., T. Otten, B. Vyshnevskiy, and O. Narvskaya. 2003. Allele-specific rpoB PCR assays 
for detection of rifampin-resistant Mycobacterium tuberculosis in sputum smears. 
Antimicrob.Agents Chemother. 47:2231-2235. 
 8.  Murphy, D. J. and J. R. Brown. 2008. Novel drug target strategies against Mycobacterium 
tuberculosis. Curr.Opin.Microbiol. 11:422-427. 
 9.  Sacks, L. V. and R. E. Behrman. 2008. Developing new drugs for the treatment of drug-resistant 
tuberculosis: a regulatory perspective. Tuberculosis.(Edinb.) 88 Suppl 1:S93-100. 
 10.  Srivastava, K., R. Das, P. Jakhmola, P. Gupta, D. S. Chauhan, V. D. Sharma, H. B. Singh, A. S. 
Sachan, and V. M. Katoch. 2004. Correlation of mutations detected by INNO-LiPA with levels of 
rifampicin resistance in Mycobacterium tuberculosis. Indian J.Med.Res. 120:100-105. 
 11.  Streicher, E. M., R. M. Warren, C. Kewley, J. Simpson, N. Rastogi, C. Sola, G. D. van der Spuy, P. 
D. van Helden, and T. C. Victor. 2004. Genotypic and phenotypic characterization of drug-resistant 
Mycobacterium tuberculosis isolates from rural districts of the Western Cape Province of South 
Africa. J.Clin.Microbiol. 42:891-894. 
 12.  Taniguchi, H., H. Aramaki, Y. Nikaido, Y. Mizuguchi, M. Nakamura, T. Koga, and S. Yoshida. 1996. 
Rifampicin resistance and mutation of the rpoB gene in Mycobacterium tuberculosis. FEMS 
Microbiol.Lett. 144:103-108. 
 13.  Telenti, A., P. Imboden, F. Marchesi, D. Lowrie, S. Cole, M. J. Colston, L. Matter, K. Schopfer, and 
T. Bodmer. 1993. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. 
Lancet 341:647-650. 
 14.  van Soolingen, D., P. E. de Haas, H. R. van Doorn, E. Kuijper, H. Rinder, and M. W. Borgdorff. 
2000. Mutations at amino acid position 315 of the katG gene are associated with high-level 
resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium 
tuberculosis in the Netherlands. J.Infect.Dis. 182:1788-1790. 
 15.  Victor, T. C., E. M. Streicher, C. Kewley, A. M. Jordaan, G. D. van der Spuy, M. Bosman, H. Louw, 
M. Murray, D. Young, P. D. van Helden, and R. M. Warren. 2007. Spread of an emerging 
Mycobacterium tuberculosis drug-resistant strain in the western Cape of South Africa. 
Int.J.Tuberc.Lung Dis. 11:195-201. 
6 
 
 16.  World Health Organization. 2007. WHO REPORT 2007 Global Tuberculosis Control Surveilance, 
Planning, Financing, p. 3-267.  
 17.  Zaczek, A., A. Brzostek, E. ugustynowicz-Kopec, Z. Zwolska, and J. Dziadek. 2009. Genetic 
evaluation of relationship between mutations in rpoB and resistance of Mycobacterium 
tuberculosis to rifampin. BMC.Microbiol. 9:10. 
 
7 
 
 
 
 
 
 
 
 
 
 
  
CHAPTER 2 
LITERATURE REVIEW 
 
 
 
MECHANISMS THAT DEFINE THE LEVEL OF DRUG RESISTANCE IN MYCOBACTERIA 
 
 
 
8 
 
Introduction 
 
Bacteria can develop resistance to antibiotics through spontaneous chromosomal mutations followed by 
natural selection upon antibiotic exposure.  The genetic information generated by these chromosomal 
alterations will be inherited by their progeny (127). Bacteria also have the ability to transfer this genetic 
information to other bacteria of the same or distant-related species through horizontal transfer (or plasmid 
exchange) (13). Horizontal gene transfer can be achieved by transduction, transformation or bacterial 
conjugation (96). 
 
Mycobacterium tuberculosis (M. tuberculosis), the causative bacteria of Tuberculosis (TB), does not 
contain plasmids (134). This pathogen develops resistance to numerous antibiotics through the acquisition 
of spontaneous chromosomal mutations in a variety of genes (Table 2.1). Drug resistant mutants are 
subsequently selected as a result of ineffective treatment or non-compliance by the patient (59). Other 
factors promoting the development of drug resistance include the use of low quality drugs, mal absorption 
and the failure to use standardized short-course chemotherapy (52,102). Amplification of resistance 
results from the ineffective management of the TB control program, improper diagnosis, and diagnostic 
delay (131). 
 
Four groups of drug resistance have been described; Mono resistance is defined as resistance to a single 
anti-TB drug, multiple resistance is defined as resistance to more than one of the first line drugs, but 
susceptible to Isoniazid (INH) and/or Rifampicin (RIF), multi-drug resistant (MDR) TB is defined as M. 
tuberculosis strains that are resistant to the two most important first-line antibiotics, Isoniazid (INH) and 
Rifampicin (RIF), whereas extensively drug resistant (XDR)-TB is defined as MDR-TB with addition 
resistance to any Fluoroquinolone (FQ) and one of the injectable antibiotics i.e. Kanamycin, Amikacin 
and Capreomycin (60). More recently a further definition has been described, namely totally drug 
resistant TB (TDR) which is defined as MDR strains resistant to all second-line drugs (125).  
 
Drug resistance in Mycobacteria is either intrinsic (natural) or acquired (chromosomal mutation). Intrinsic 
resistance is attributed to; i) the permeability of the lipid-rich hydrophobic cell wall which consists of 
9 
 
mycolic acids, arabino and peptidoglycans (26,58), ii) expression of active efflux systems (36,37), iii) the 
modification and inactivation of the drug, iv) absence of enzymes required to activate the prodrug, v) 
alteration in the structure of the drug target (reduced affinity of the drug for the target), and vi) altered 
expression of the drug target (Figure 2.1).  Acquired resistance is attributed to chromosomal changes in 
regulatory domains and target genes leading to; i) the inability activate the prodrug, ii) alteration of the 
drug target (reduced affinity of the drug for the target), and iii) alteration in expression of drug target 
(Figure 2.1). Both intrinsic and acquired mechanisms define the minimum inhibition concentration (MIC) 
of a drug required to kill 99% of the bacterial population. 
 
 
 
Figure 2.1: Mechanisms of drug resistance in mycobacteria. 
 
The molecular mechanisms of acquired drug resistance in mycobacteria have been studied extensively 
and several reviews have been published on this topic (59,99,104).  Table 2.1 summarizes the genes 
involved in conferring acquired resistance to both first and second line anti-TB drugs. This review aims to 
describe mechanisms which affect the level of intrinsic and acquired drug resistance.  
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GENERAL OVERVIEW OF GENE REGULATION 
 
Gene regulation in bacteria is mediated by either proteins that act as transcriptional regulators (repressors 
or activators) or modulation of the RNA structure (also called transcription attenuation) (25). 
Transcriptional attenuation is the process where mRNA is alternatively folded in the leader region 
upstream of the coding sequence. This results in premature attenuation of transcription. Bacteria also 
make use of operon systems to coordinately transcribe sets of genes encoding functionally related 
proteins.  These genetic mechanisms can control metabolic events in response to environmental 
conditions which may include exposure to drugs (63). An operon generally consists of a promoter, 
operator, two or more structural genes and a repressor gene. The structural genes are regulated by an 
allosteric repressor molecule transcribed from the repressor gene. This repressor molecule interacts with a 
regulatory element, the operator, and represses transcription until it interacts with a chemical inducer 
(Figure 2.2A) (128). This interferes with RNA polymerase which binds to the promoter region and 
transcription of the structural genes is repressed. However, in the presence of an inducer molecule, it 
binds to the repressor protein and causes an allosteric conformational change of the repressor protein 
(Figure 2.2B). This reduces the affinity of the repressor protein for the operator, which relieves the 
negative regulation, allowing the RNA polymerase to transcribe the structural genes. 
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Figure 2.2: Illustration of lac operon and the effects in the absence of the substrate (Fig 2.2A) and in the 
presence of the substrate (Fig 2.2B). 
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MECHANISMS AFFECTING THE LEVEL OF INTRINSIC AND ACQUIRED DRUG 
RESISTANCE 
 
2.1. Failure to activate the drug  
 
Isoniazid (INH): INH is one of the most important first line anti-TB drugs.  On entry into the cell by 
passive diffusion, INH is activated by the catalase-peroxidase enzyme (KatG) encoded by the katG gene 
to form isonicotinic acyl anions and other reactive radicals. It is speculated that the metabolic products 
that are generated by the activation of INH bind to and inactivate the protein encoded by the inhA gene 
which is an enoyl-acyl carrier protein (ACP) reductase, involved in mycolic acid synthesis (10). 
Inactivation of inhA leads to the inhibition of cell wall synthesis and cell death (75,138). Thus the MIC 
for INH is defined by the rate at which INH is activated and not by the interaction of the activated 
metabolic products with cellular processes (86). Accordingly, the INH MIC is largely determined by the 
rate of expression of katG. In contrast to E. coli, expression of the katG gene in members of the M. 
tuberculosis complex (M. tuberculosis, M. bovis, M. africanum and M. microti) is not regulated oxyR 
(114,115) as this gene is deleted in these members.  Regulation of expression of the katG gene is thought 
to occur through alternative regulatory proteins present in the genome (42,43,103). Previous studies in 
non-mycobacterial species have suggested that expression of oxidative stress genes is coupled with iron 
metabolism via the ferric uptake regulator, Fur. This prompted scientists to investigate the relationship 
between the fur ortholoques in M. tuberculosis and katG expression.  Whole genome sequencing of M. 
tuberculosis revealed that a fur-like gene, furA, is positioned 40 bp upstream from katG and forms a co-
transcribed operon (43,81,86). Zhart and colleagues demonstrated that katG is over-expressed in a FurA 
knockout mutant leading to hypersensitivity to INH (decrease MIC) (133). This suggests that FurA acts as 
a repressor of katG expression  (86,133). FurA negatively regulates the expression of the furA gene by 
binding to a region upstream of the furA gene (97). To date, only two furA mutant clinical isolates have 
been reported (86). However, these strains also had mutations in the katG gene and therefore it was 
speculated that the furA mutations may modulate the level of INH resistance. 
 
Ethionamide (ETH): ETH is a structural analogue of INH which doesn‟t show cross resistance with INH 
and is thus used as a second-line drug for the treatment of MDR-TB and XDR-TB. ETH is a prodrug that 
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is activated by EthA (a FAD-containing monooxygenase enzyme), to generate metabolic by-products 
which exert a toxic effect upon the synthesis of the mycolic acid constituents of the mycobacterial cell 
wall (14,15,41,124).  The expression of ethA is negatively regulated by its neighbouring gene, ethR, 
which encodes the protein EthR  (15,41).  EthR is a member of the TetR/CamR family of transcriptional 
regulators which binds cooperatively as a homo-octamer to the ethA operator (9), 5 to 16 nucleotides 
upstream from the ethA start codon (45). Thus, expression of ethR defines the level of expression of ethA 
which in turn determines the level the innate resistance to ETH (49). This is supported by the observation 
that over expression of ethR leads to repression of expression of ethA and to ETH resistance (15,41). 
Conversely, conditions leading to the down-regulation of ethR expresssion or mutation in ethR gene 
increases ETH susceptibility (lower MIC) (15). Similarly, the addition of compounds which bind to EthR 
(such as HexOc) and thereby prevent its binding to the ethA operator (50), promote expression of the ethA 
gene, continuous activation of ETH and increased ETH susceptibility (15,41).  
 
2.2.  Inactivation of drug 
 
Aminoglycosides: Streptomycin (STR), Capreomycin (CAP) Amikacin (AM) and Kanamycin (KAN) are 
aminoglycosides used in the treatment of drug susceptible TB, MDR and XDR-TB. These compounds 
inhibit protein synthesis by binding to the ribosomes which are responsible for peptide elongation during 
translation (46,110). In M. tuberculosis, resistance to aminoglycosides develops through mutations in the 
rrs and rpsl genes encoding for the 16S rRNA and S12 ribosomal protein, respectively (88). In certain 
Mycobacteria (i.e. M. fortuitum, M. chelonei, M. tuberculosis and M. smegmatis  (3,4,74)) 
aminoglycoside resistance also develops through the expression of acetyltransferases which transfer a 
functional group to the aminoglycoside structure,  thereby preventing binding of the aminoglycoside to 
the ribosome (67,130). Three types of modifications have been demonstrated: O-phosphotransferases, O-
nucleotidyltransferases and N-acetyltransferases (67). This modification prevents the binding of the 
aminoglycoside to the ribosome, the molecular target of the antibiotic (67,130). N-acetyltransferases are 
the most wide spread determinants of resistance to aminoglycosides (69).  The aac(2’)-Id gene confers 
resistance to aminoglycosides (4) and is expressed at low levels conferring low level innate 
aminoglycoside resistance. Up-regulation of expression of the aac(2’)-Id gene by cloning the gene 
adjacent to a  strong mycobacterial promoters resulted in higher aminoglycoside MIC values (74). This 
14 
 
suggests that the level of aminoglycoside resistance depends on the strength of the promoter responsible 
for the transcription of the aac(2’)-lb (74).  
 
The aph(3”)-lc gene, encoding for a 3”-O-phosphotransferase, has been shown to confer resistance to 
streptomycin in M. fortuitum, however, no homologues of this gene could be found in other 
Mycobacterium species (93). Also no additional information is available on the transcriptional regulation 
for this gene in M. fortuitum. However in Pseudomonas aeruginosa the aph(3’)-llb gene (encoding for an 
aminoglycoside-phosotransferase gene) is under the positive control of a surrogate regulator HpaA (135). 
Therefore the transcriptional regulation for aph(3”)-lc needs to be investigated further in mycobacteria. 
 
Isoniazid: INH is inactivated when an acetyl group is transferred to the free amino group to form an 
acetylamide (84). This reaction is catalyzed by the human N-Acetyl transferase (NAT2) (105), as well as 
by the M. tuberculosis NAT enzyme (122).  Heterologous expression of M. tuberculosis NAT in M. 
smegmatis resulted in a three-fold increase in INH resistance (84) while increased sensitivity to INH was 
observed in a M. smegmatis nat knockout mutant (85). Both of the above studies speculated that NAT 
might be involved in innate INH resistance.  However, this is controversial as a recent study has 
demonstrated through kinetic characterization that INH is a poor substrate for the NAT enzyme (107).  
 
Rifampicin (RIF): RIF binds to the beta subunit of the RNA polymerase, thereby hindering transcription  
(119). Single nucleotide substitutions in the 81 bp core region of the rpoβ gene (also known as the RIF 
resistance determining region; RRDR) are associated with RIF resistance altering the structural 
conformational of the RNA polymerase thereby decreasing the binding affinity between RIF and the RNA 
polymerase (120). Interestingly, M. smegmatis demonstrates RIF resistance in the absence of rpoB 
mutations (53).  This suggests that other mechanisms are involved in RIF resistance. Many fast growing 
mycobacterium strains, including M. smegmatis, M chelonae, M. flavescens, M. vaccae and M. 
parafortuitum, have been reported to inactivate RIF by ADP-ribosylation (118). It has been shown that 
RIF ribosylation is a major contributor to low level RIF resistance in M. smegmatis (87) and is encoded 
by the arr-ms gene. The ADP-ribosyl transferases transfer an ADP-ribose unit to a susceptible amino acid 
residue on the target protein with the loss of a nicotinamide molecule (16). Significantly, this genes is 
absent from the M. tuberculosis genome thereby explaining RIF susceptibility in pan susceptible isolates. 
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2.3. Alteration of drug target’s activity 
 
It is well documented that acquired drug resistance in mycobacteria develops through spontaneously 
chromosomal mutations in the gene encoding for the drug target (59). It is now known that different 
levels of drug resistance can arise through mutations at different positions in the target gene (132) or 
mutations in other non-target genes (123).  
 
Isoniazid: Mutations at different positions in the inhA gene, resulting in structural changes in InhA 
protein have been reported to confer isoniazid resistance, however these mutations are rarely seen in 
clinical isolates (88). Mutations in this gene generally confers low level resistance (<0.5 µg/ml)  (1,90). 
Many of these low level resistance clinical isolates do not have mutations in the katG gene (1).  Mutations 
in the katG gene encoding for catalase perozidase responsible for the activation of INH, also confers 
resistance to INH. These mutations result in high level resistance to INH and occur in 30-60% of all INH 
resistant isolates (1,88). 
 
Rifampicin: RIF binds to the beta subunit of the RNA polymerase, thereby hindering transcription  (119). 
Single nucleotide substitutions in the 81 bp core region of the rpoβ gene (also known as the RIF 
resistance determining region; RRDR) are associated with RIF resistance (REF) by altering the structural 
conformational of the RNA polymerase thereby decreasing the binding affinity between RIF and the RNA 
polymerase. The level of RIF resistance in M. tuberculosis is dependent on the position of the mutation in 
the rpoB gene, however, most rpoB mutations cause resistance above the critical concentration of 2 
g/ml. The MIC for RIF has been reported to range from 32 to 256 on 7H10 solid media (56) (Table 2.2). 
In clinical isolates mutations in codon Ser531 and His526 account for more than 75% of RIF resistance. 
The frequency at which these mutations occur is thought to reflect the fitness cost incurred by the 
respective mutation (22,70).  
 
Ethambutol (EMB): EMB is a first line anti-TB drug which inhibits the synthesis of cell wall arabinan, a 
component of the cell wall structural molecule, arabinogalactan. EMB binds to arbinosyltransferases 
which is encoded by the emb genes (17,116). The inhibition of arabinan synthesis leads to accumulation 
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of mycolic acids and eventually to cell death (89).  Mutations at codon 306 in the embB gene was usually 
associated with high level EMB resistance (113). However, recently it has been shown that Met306Leu 
substitutions are associated with high level EMB resistance, while Met306Ile substitutions are associated 
with low level EMB resistance  (57,111).  
 
Streptomycin (STR): STR is an alternative first line drug used in the treatment of TB. In M. Tuberculosis 
the effect of STR has been demonstrated to take place at ribosomal level where it interacts with the 16S 
rRNA and S12 ribosomal protein (rrs and rpsL) (109). This results in the induction of ribosomal changes, 
which cause misreading of the mRNA and inhibition of protein synthesis (55). Mutations associated with 
STR resistance have been identified in the rrs and rpsL genes. In addition it has been shown that one-third 
of STR resistant clinical isolates nucleotide changes in these genes, suggesting that other mechanisms for 
STR resistance exist in M. Tuberculosis  (48,79).  It has been shown that mutations in the rpsL gene are 
associated with high level resistance, while mutations in the rrs gene are associated with intermediate 
level of resistance (73).  Isolates with a wild-type rpsL and rrs genotype exhibited a low-level resistance 
phenotype (73).   
 
Ofloxacin (OFX): OFX is a FQ used as a second line drugs for the treatment of MDR-TB.  In M. 
tuberculosis it targets and inactivates a type II DNA polymerase, DNA gyrase (44) (117). Mutations in 
the genes encoding for the DNA gyrase, gyrA and gyrB, are responsible for conferring resistance to FQ by 
introducing negative supercoils in the circular DNA molecules (88).  Asp94Gly substitutions in the gyrA 
gene are associated with high level OFX resistance (61). It is speculated that this specific mutation render 
the DNA gyrased conformation more difficult for FQ‟s to bind. This would result in higher MIC values 
for this drug. 
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2.4. Differential expression of drug target 
 
Isoniazid: Mutations in the promoter region of inhA gene are more frequently seen in clinical isolates. 
These mutations lead to the over-expression of the inhA gene resulting in an increase in the concentration 
if InhA which partially overcomes the toxic metabolic byproducts generated by KatG  leading to low 
level INH (62,68).  
 
Ethambutol:  EMB resitance is further example where transcriptional regulation of the drug target would 
affect the level of drug resistance (REF). The embCAB-operon which encodes the target genes EmbA, 
EmbB and EmbC is found in most mycobacterial species. EmbA and EmbB are enzymes that catalyse the 
arabinosylation of arabinogalactan, while EmbC synthesises lipoarabinomannan (47,136). In M. avium 
the emb gene cluster contains only the embAB genes and an additional putative transcriptional regulator, 
embR, immediately upstream of the embAB genes (17,89). EmbR is a multidomain protein and possesses 
a DNA binding winged helix-turn-helix domain, a bacterial transcription activation domain and a 
forkhead-associated (FHA) domain (101). The three dimensional structure of EmbR suggests that it acts 
as a transcriptional regulator (6).  It was observed that EmbR acts as a transcriptional regulator by 
modulating the arabinosyltransferase activity in vitro (17).  In the M. tuberculosis and M. smegmatis 
genome, an embR homolog is located 2 MB from the embCAB locus, leading to the hypothesis that this 
homolog may also modulate the level of arbinosyltransferase activity (34,89).  
 
The Ser/Thr protein kinase, PnkH is another protein involved in transcriptional regulation of embCAB 
(76). This Ser/Thr protein kinase is located in the mycobacterial membrane and therefore it is speculated 
that PnkH is autophosphorylated on sensing external stimuli. This significantly increases the protein 
kinase activity (76). In turn PnkH phosphorylates the FHA domain of EmbR, which enhances the binding 
activity towards the promoter regions of embCAB (76,101) thereby enhancing transcription leading to a 
higher concentration of EmbB, EmbA and EmbC, influencing the lipoarabinomannan:lipomannan ratio in 
the cell. Similarly, Mutations in the EmbR FHA domain were previously shown to be associated with 
EMB resistance (89). 
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Since EMB resistance depends on the gene copy number of EmbB and EmbA, increased expression of 
embCAB through increased activation by the PnkH-EmbR pair would be predicted to result in increased 
levels EMB resistance (17,101).  
 
2.5.  Increased efflux of drug 
Low-level intrinsic resistance in the absence of mutations in the known drug resistance causing genes 
may be due to either permeability or active efflux. Thus,  the intracellular concentration of a given drug 
will depend on the balance between its influx and efflux (126). This balance may be disturbed by 
treatment as antibiotics can serve as inducers, regulating the expression of efflux pumps at the level of 
gene transcription by interacting with regulatory systems (37). Bacterial drug efflux pumps are generally 
classified on the basis of their energy source (64). The ATP binding cassette (ABC) superfamily are 
considered as primary transporters and make use of ATP as an energy source (19,23,37,82). The Major 
Facilitator Superfamily (MFS) (37,106,108), Small Multidrug Resistance (SMR) family (65), Resistance-
Nodulation-cell Division (RND) family (34,82) and Multidrug And Toxic compounds Extrusion family 
(MATE) are secondary transporters which are driven by proton (H
+
) influx (37).  
 
In Mycobacteria the following efflux pumps involved in drug resistance have been identified and 
described. 
 
MFS efflux pumps 
 
To date, six MFS efflux pumps have been described in Mycobacteria that may define the level of intrinsic 
resistance to various anti-TB drugs. The Rv1634 efflux pump in M. tuberculosis conferred resistance to 
FQ (ciprofloxacin, norfloxacin, ofloxacin, lomefloxacin) when over expressed in M. smegmatis (38).   
 
19 
 
The Tet(V) efflux pump, isolated from M. smegmatis, was shown to increase the minimum inhibitory 
concentration (MIC) of tetracycline when over expressed (40). However, this efflux pump has only been 
identified in M. smegmatis and M. fortuitum (40).  
 
The Tap efflux pump from M. fortuitium increased resistance to aminoglycosides when expressed in M. 
smegmatis (2). The activity of Tap efflux pumps in M. fortunium can be inhibited by several efflux pump 
inhibitors such as reserpine and CCCP, leading to lower levels of resistance or increased susceptibility 
(91). Its homologue, Rv1258c, in M. tuberculosis conferred resistance only to tetracycline (2). However, 
analysis of Rv1258c gene expression of a clinical M. tuberculosis isolate exposed to RIF and ofloxocin 
showed increased transcript levels (106). Although RIF and OFX were not found to be substrates of Tap 
(2), Sidiqi et al suggested that the high level resistance to rifampicin could by explained by the over 
expression of Rv1258c (106). This suggests that certain efflux pumps may be induced by exposure to 
drugs.  
 
The P55 efflux pump in M. bovis and its M. tuberculosis homologue, Rv1410c, also confers resistance to 
aminoglycosides and tetracycline (20) (108). Expressing P55 in M. smegmatis resulted in an 8-fold 
increase in the MIC for STR (108). This efflux pump could explain STR resistance in STR-resistant M. 
tuberculosis isolates that do not harbour mutations in the rrs and rpsL genes (88). Rv1410c is organized in 
an operon with lprG which encodes for a membrane protein, P27 (20). Although the function of this gene 
product is unknown, disruption of lprG abrogates the expression of Rv1410c leading to strong attenuation 
of virulence in mice (21). This suggested that P27 may have a direct or indirect regulatory role in P55 
expression. Recently it has been shown that the deletion of P55 in M. Bovis BCG resulted in increased 
susceptibility to a range of toxic compounds including RIF and clofazimine  (92). 
 
Expression of the M. tuberculosis H37Rv epfA gene in M. smegmatis increased in response to INH 
treatment (129). EpfA encodes for a putative efflux protein (EfpA) with a similar secondary structure to 
that of members of a transporter family known for the mediation of antibiotic resistance in bacteria and 
yeast (QacA transporter family) (37). Although no association between the EfpA and drug resistance 
could be made, the deletion of the epfA homologue in M. smegmatis increased the susceptibility of the 
isolates to ethidium bromide, gentamicin, FQ and acriflavine (37).  
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Limited experimental data exists to provide evidence that the regulation of efflux genes influence the 
level of drug resistance in M. tuberculosis. However, functional analysis has been done extensively on the 
MFS LrfA efflux pump (117). The lfrA gene in M. smegmatis encodes a transporter which confers low-
level resistance to fluoroquinolones, acriflavine and ethidiumbromide when over expressed (66,117). 
Disruption of lfrA resulted in increased susceptibility to FQ, acriflavine and ethidiumbromide (65,98). 
Regulatory mutations leading to constitutive expression and induction by the substrates of the pump may 
lead to increased expression of lfrA (37). 
 
An open reading frame (570 bp), lfrR, upstream of the lfrA gene with homology to several TetR 
transcriptional proteins was previously identified (65). TetR transcriptional regulators are characterized 
by a conserved DNA binding domain (helix-turn-helix at the N-terminal) and a ligand binding domain (C-
terminal region). Binding of an inducing ligand to the C-terminal region results in conformational 
changes in the N-terminal region, reducing its affinity to its target promoter DNA (54). It was shown that 
a 390 base pare deletion of lfrR resulted in increased CIP and norfloxacin resistance and increased lfrA 
expression (65). This suggested that LfrR acts as a repressor that negatively regulates the production of 
LfrA. Realtime (RT)-PCR  experiments revealed that the lfrR and lfrA genes are organized as an operon, 
with a promoter 220 base pares upstream from lfrR (27). LfrR represses lfrA expression by binding 
directly to the promoter region of lfR-lfA (27). 
 
Acriflavine acts as a ligand inducer for LfrR (27). It induces a conformational change in this repressor, 
leading to a reduction in its DNA binding affinity, which may lead to increased expression of lfrA  (27). 
Although ciprofloxin acts as a substrate of lfrA it showed no interaction with LfrR, suggesting that not all 
substrates of lfrA act as inducers (27). The combination of mutations gyrA and gyrB genes (72) and a FQ 
efflux pump may lead to different (increased) levels of drug resistance. As there is no known homology of 
lfrA in M. tuberculosis it is speculated that the regulation of efflux pumps may be involved in resistance 
to FQ in M. tuberculosis (37,38). 
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An additional 16 putative MFS drug efflux pumps have been identified in M. tuberculosis through whole 
genome analysis and comparative bioinformatics (38), however, their role in intrinsic drug resistance 
remains to be determined. 
 
SMR family drug transporters  
 
Only one member of the SMR family of drug transporters for mycobacterium has been described thus far. 
The mmr-like gene (encoding for the protein Mmr) are present in M. tuberculosis (Rv3065), M. simiae, M. 
gordonae, M. marinum, M. smegmatis and M. bovis (39).  When the mmr gene from M. tuberculosis was 
expressed in M. smegmatis, it conferred resistance to a number of toxins and drugs such as tetraphenyl 
phosphonium, ethidiumbromide, erythromycin, safranin O and pyronin Y (39). Furthermore, the deletion 
of the mmr homologue in M. smegmatis increases the susceptibility of the bacterium to cationic dyes and 
FQ, suggesting that this protein plays an important role in the intrinsic resistance of M. smegmatis (65).  
 
RND drug transporters 
 
Sequencing and analysis of the whole genome sequence of M. tuberculosis revealed the presence of 13 
putative transmembrane proteins which are members of the RND family of drug transporters (34). The 
MmpL (mycobacterial membrane proteins, large) proteins are confined to mycobacteria (83). Over 
expression of the M. tuberculosis mmpL7 gene M. smegmatis increase resistance to INH to a level 32 
times higher that the MIC of the wild type (83), suggesting that MmpL plays a role in the detoxification 
process by which M. tuberculosis limits the effects of INH. 
 
ABC drug transporters 
 
A total of 37 ABC transporter genes have been identified in the genome M. tuberculosis (23). The ABC 
transporters are characterised by at least 4 functional domains (two membrane-spanning domains and two 
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nucleotide-binding domains), however, only a few have been shown to be associated with drug resistance 
in mycobacteria. Two operons containing ABC transporter genes, doxorubicin-resistance operon (drAB) 
(34) and the Rv2686c-Rv2687c-Rv2688c operon, have been described for M. tuberculosis. Whole genome 
sequencing of M. tuberculosis, revealed the presence of the doxorubicin-resistance operon, drrAB, which 
encodes for an ABC drug transporter (34). DrrAB confers resistance to antibiotics such as tetracycline, 
erythromycin, EMB, norfloxacin and STR when expressed in M. smegmatis. The resistant phenotype 
could be reversed by efflux pump inhibitors such as verapamil and reserpine (30). The Rv2686c-Rv2687c-
Rv2688c operon encodes for an ABC transporter responsible for FQ efflux (82). The pump confers 
resistance to CIP (8 x MIC) and norfloxacin (2 x MIC) when over expressed in M. smegmatis (82). 
 
The phosphate specific transporter (Pst) is involved in phosphate transport and has been reported in 
numerous bacteria, including M. tuberculosis  (12,24). PstB overexpression was observed in an in vitro 
generated CIP mutant (11). Efflux pump inhibitors, reserpine and verapamil, were shown to reverse the 
resistance phenotype, suggesting that PstB plays a role in increasing CIP resistance levels (11). 
Sensitivity to CIP, OFL and sparfloxacin was observed with the disruption of the pst operon (19).   
 
2.6.  Drug tolerance 
Little is known about the functional roles of M. tuberculosis genes which are up regulated in response to 
an antibiotic (33). It is hypothesized that such transcriptional changes might induce antimicrobial 
tolerance and thereby defining the level of intrinsic drug resistance. An example of antibiotic-induced 
genes in M. tuberculosis is the iniBAC operon which is induced by INH and EMB (7,8). Over expression 
of M. tuberculosis iniA gene in M. bovis BCG upon exposure to INH and EMB resulted in a tolerance-
like phenotype to these antibiotics (32). It is suggested that IniA preserves cellular functions normally 
disrupted by these antibiotics (32). Deletions of iniA in M. tuberculosis increases its susceptibly to INH 
(32).  
 
In addition, it has been shown that the lsr2 gene product down regulates the transcription of the iniBAC 
genes in M. tuberculosis (33)). Lsr2 is a small histone-like protein that directly interacts with DNA, 
forming large oligomeric complexes through DNA bridging (29,33). Deletion of lsr2 in M. smegmatis 
resulted in increased resistance to EMB (33). Thus a mutation or reduced expression in the lsr2 gene, 
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leading to decreased DNA binding affinity might result in increased expression of iniBAC and resistance 
to INH and EMB.  
 
The M. tuberculosis genome contains 7 whiB-like genes (whiB1-7) which encode for putative 
transcriptional regulators (34,80). Geiman et al showed that INH, ethambutol and cycloserine stimulated 
whiB2 transcription. Aminoglycosides such as STR and kanamycin induced the transcription of whiB7 
(51). In Streptomyces lividans and S. coelicolor whiB2 is responsible for multi-drug resistance and 
associated with higher levels of drug resistance (18,78). Thus it was suggested that whiB7 might play a 
similar role in the drug resistance of M. tuberculosis (78). Exposure of M. tuberculosis to STR led to the 
increased expression of whiB7 (78). Microarray analysis revealed that upon tetracycline exposure the 
expression of 12 other genes was temporally dependant on the initial induction of whiB7 (78).  This 
suggests that WhiB7 acts as a regulator, activating a regulon involved in intrinsic antibiotic resistance 
(78).  
 
CONCLUDING REMARKS 
 
It is now known that drug resistance in Mycobacteria is influenced by mechanisms other than the classical 
drug resistant gene causing mutations. This review discussed  various mechanisms by which 
Mycobacteria have evolved to elevate its level of resistance to certain drugs. Varying levels of resistance 
are contributed by acient intrinsic mechanisms such as the rigid mycobacteria cell wall and active efflux 
pumps. Mycobacteria also has  aquired novel mechanisms through chromosomal alterations in non-
classical drug resitance genes and regulatory units. The combination of these mechanisms would result in 
strains which become hyper resistant to anti-TB drugs. This demonstrates the complexicity of drug 
resistance in Mycobacteria. The indentification of novel mehanisms that regulate the level of drug 
resistance can serve as potential candidates for future drug design to improve the treatment of TB. 
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Table 2.1: Summary of genes associated with drug resistance in M. tubercolosis. 
 Drug Drug target Mutations  Enzyme Reference 
F
ir
st
 l
in
e 
d
ru
g
s 
Isoniazid (INH) InhA katG Catalase peroxidase (31,88,90,94) 
ahpC Alkyl hydroperoxide 
inhA fatty acid enoyl acyl carrier 
protein reductase A 
kasA β-ketoacyl-ACP 
ndh NADH dehydrogenease 
Rifampicin (RIF) β subunit RNA 
polymerase 
rpoB β subunit RNA polymerase (28,119) 
Pyrazinamide (PZA) No specific target pncA Pyrazinomidase (100,137) 
Ethambutol (EMB) embB embCAB arabinosyl transferase (88,95,121)  
S
ec
o
n
d
 l
in
e 
d
r
u
g
s 
A
m
in
o
g
ly
co
si
d
es
 
Streptomycin (STR) 16S rRNA ribosomal 
subunits 
rpsl  16S rRNA ribosomal subunits (5,71,95)  
rrs 
tlyA  
Capreomycin (CAP) 
Kanamycin (KAN) 
Aminokacin  (AMI) 
Ethionamide (ETH) InhA inhA fatty acid enoyl acyl carrier 
protein reductase A 
(45,77) 
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ethA flavin monooxygenase  
ethR Transcriptional regulator 
Fluoroquinolones (FQ) DNA gyrase gyrA DNA gyrase (44) 
gyrB 
 
Table 2.2:  Level of RIF resistance in clinical isolates and in vitro selected mutants. 
 Codon MIC (µl/ml) Reference 
Clinical His526Tyr 10-64 (112) 
512 (35) 
Ser531Leu > 64 (112) 
>512 (35) 
In Vitro (selected 
mutants) 
Ser522Leu > 16 (70) 
8-16 (56) 
His526Tyr > 32 (70) 
≥32 - ≥256 (56) 
His531Trp/Leu > 32 (70) 
≥ 32 - ≥ 256 (56) 
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Table 2.3: Transcriptional regulators of the molecular mechanisms of drug resistance in mycobacteria. 
 Regulator gene Regulator 
protein 
Target 
genes of 
regulator 
Drug resistance 
effected 
References 
A
ct
iv
a
to
r 
embR EmbR EmbCAB Ethambutol (17,89,101) 
whiB7 WhiB7 Regulon  (78) 
R
ep
re
ss
o
r 
ethR EthR ethA Ethionamide (45,78) 
furA Fur A katG Isoniazid (86,133) 
lfrR LfrR lfrA Fluoriquinolones (66,98) 
lsr2 Lsr2 iniBAC Isoniazid 
Ethambutol 
(32,33,89,90) 
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CHAPTER 3 
MATERIALS AND METHODS 
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A three pronged approach, using proteomics, transcriptomic and genomic methods were used to enhance 
the possibility to identify mechanisms which can explain varying levels of RIF resistance in two closely 
related clinical isolates. An outline of the experimental procedures is given in Figure 3.1. 
 
 
 
 
 
Figure 3.1: Summary of techniques used in this study 
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3.1. STRAIN SELECTION 
Well characterized clinical isolates (R439 and R451) of M. tuberculosis was selected from an existing 
local sample bank maintained at the Stellenbosch University, Western Cape, South Africa. In this setting 
three dominant strain groups are present: Beijing, Low Copy Clade (LCC) and LAM (Latin-American 
and Mediterranean) (5). These two clinical isolates are from the same LCC evolutionary lineage (identical 
IS6110 RFLP and spoligotype fingerprints) and were selected based on the having identical mutations in 
the katG (315 ACA), emb (306 ATA), pncA (Del58) and rpoB gene (531 TTG) with intermediate (R439) 
and high (R451) levels of RIF resistance (Table 3.1) (PhD thesis, Gail E. Louw, 2009). No low MIC 
strain was selected as isolates were exposed to 2ug/ml, which would have a killing effect on the low MIC 
strain. MICs are defined as the lowest concentration of the compound capable of inhibiting visible growth 
of a microorganism after overnight incubation (1,3). 
 
Table 3.1: Characteristics of selected clinical isolates  
Isolate Family Spoligotype Cluster IS6110 RFLP 
RIF MIC 
(ug/ml) 
R439
a
 
LCC 115 DRF150 
IS6110 RFLP
...
 
60 
R451
b
 170 
Legend to table 4.3: a - LCC RIF resistant isolate with intermediate RIF resistance levels;  
b - LCC RIF resistant isolate with high RIF resistance levels 
 
 
3.2. CULTIVATION OF M. TUBERCULOSIS STRAINS 
 
Preparation of freezer stock: 
Strains were first grown on Lowenstein-Jensen (LJ) solid medium with continuous aeration for 
approximately three weeks at 37°C. A starter culture was set up by scraping “buff” colored colonies from 
LJ‟s slants and inoculating it into 5 ml of 7H9 Middlebrook medium (Becton, Dickinson Microbiology 
system, Sparks, USA), supplemented with 10% albumin-dextrose-catalase (ADC),  with 0.2% (v/v) 
glycerol (Merck Laboratories, Saarchem, Gauteng, SA) and 0.1% Tween80 (Becton, Microbiology 
systems, Sparks, USA). Cultures were then grown in filtered screw cap tissue culture flasks (Greiner Bio-
one, Maybachstreet, Germany) without shaking for 37°C until an optical density (OD600) of 0.6-0.8 were 
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reached. The cultures were then inspected for contamination by Ziehl-Neelsen (ZN) staining and cultured 
onto blood agar plates. The primary cultures were subsequently sub-cultured in 10 ml 7H9 Middlebrook 
medium supplemented with ADC and incubated at 37°C. After an OD of 0.7-0.8 has been reached the 
cultures were re-inspected for contamination before 50% glycerol stocks (1:1 v/v, 500µl culture and 
500µl 50% glycerol) was prepared and stored at -80°C.  
 
ZN staining and Blood agar plates: 
The presence of contaminants in the M. tuberculosis cultures were continuously monitored with ZN 
staining as well as plating the culture onto a blood agar for two days (M. tuberculosis does not grow on 
blood agar within 2 days). For ZN staining a M. tuberculosis smear was heat fixed (heated for 2 hours at 
100 °C), stained with carbol-fuchsin (Becton, Dickinson and Company, Maryland, USA), and decolorized 
with acid alcohol. The smear was then counterstained with methylene blue (Becton, Dickson and 
Company, Maryland, USA) and read under the microscope for acid-fast bacilli. M. tuberculosis, an acid-
fast bacterium, will retain dyes when heated and treated with acidified organic compounds. Therefore it 
will appear pink in a contrasting background when the ZN test is done. 
 
Setting up initial cultures for Protein and RNA experiments 
Cultures for both protein (1600ul stock into 160ml media) and RNA (60ul stock into 60ml media) 
extractions was set up by making a 1:100 dilution of the freezer stock into 7H9 Middlebrook media 
supplemented with ADC. Cultures were incubated in tissue culture flasks at 37°C until an OD600 of 0.7-
0.8 has been reached. Liquid cultures were then divided into two portions: one half of the culture served 
as control, where as the remaining half of the culture was exposed to the critical concentration of 
Rifampicin (RIF) (Becton, Dickinson and Company, Sparks, USA) (2 µg/ml) and incubated at 37 ºC for a 
further 24 hours after which either protein or RNA was extracted. The critical concentration is defined as 
the drug concentration used to differentiate between drug susceptible and drug resistant isolates. An 
isolate is determined as resistant when 1% or more of the test population grows in the presence of the 
critical concentration of the drug. This concentration was used as it would not result in a killing effect of 
high and intermediate level RIF resistant isolates. Two biological (to assess biological measurements for 
two independent experiments done on different days) and 2 technical replicates (repeated measures of one 
biological sample on the same day) was done for all isolates. 
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3.3. PROTEOMICS 
 
3.3.1.  Membrane protein  extractions of M. tuberculosis 
Cultures were centrifuged (Eppendorf, Centrifuge 5810R) in 50ml tubes (LASEC, South Africa) at 3000 
rpm for 20 minutes at 20ºC. The supernatant was discarded and the pellet re-suspended in 1 ml Phosphate 
buffer saline (PBS), pH 7.4, containing 1% (v/v) Tween80 (Merck Laboratories, Saarchem, Gauteng, SA) 
in a 2 ml screw cap tube (Whitehead Scientific, South Africa). The suspension was then centrifuged for a 
further 5 minutes at 6000 rpm. The supernatant was discarded and the resulting pellet was re suspended in 
1 ml PBS. The suspension was centrifuged for a further 5 minutes at 6000 rpm. After centrifugation the 
supernatant was discarded and an equal volume of glass beads (0.1 mm, Separations, South Africa) and 
approximately 200-300 µl lysis buffer was added to the bacterial pellet. The bacterial cells were ribolysed 
using a FastPrep FP120 ribolyser (Bio101 SAVANT, Vista, USA) at 6.5m/s for 2 x 45 seconds with 1 
minute of cooling on ice between intervals. The lysed suspension were then incubated on ice for 10 
minutes and centrifuged for 15 minutes at 13 000 rpm. The supernatant, containing the whole-cell lysate 
proteins were then filter-sterilized with a 0.22 µm Millex-GV filter (Millipore, Bangalore, India) and 
transferred to a clean 1.5ml Eppendorf tube (Merck, New Jersey, USA). 
 
The recovered whole-cell lysate (WCL) proteins were fractionated into cell wall, cytosol and membrane 
proteins. The whole-cell lysate proteins were centrifuged for 1 hour at 17 000 rpm. After centrifugation 
the supernatant were transferred to a clean 1.5ml Eppendorf tube (Merck, New Jersey, USA) and the 
pellet, containing cell wall proteins, was re-suspended in 150 μl lysis buffer. The supernatant were then 
centrifuged for 2 hours at 33 000 rpm. After centrifugation the supernatant, containing the cytosol 
proteins, were transferred to a new tube and the pellet, containing the membrane proteins were re 
suspended in 150 μl lysis buffer. The different protein fractions were stored at -20°C until needed for 
further analysis. Previous work (PhD thesis, Gail E. Louw, 2009) has shown that genes encoding proteins, 
specifically ABC transporters, are significantly differentially expressed after RIF exposure. Therefore 
only membrane proteins were used in subsequent experiments. 
 
 
 
44 
 
3.3.2.  Determination of protein concentrations and purification 
Protein concentrations were determined with the RC DC Protein assay (Bio-Rad Laboratories, Hercules, 
CA 94547) according to the manufacturer‟s instructions. The proteins were purified using the ReadyPrep 
2-D Cleanup Kit (Bio-Rad Laboratories, Hercules, CA 94547) according to the manufacturer‟s 
instructions.  
 
3.3.3. Protein separation 
Isoelectric focusing (IEF) – First dimension separation 
Two hundred µg of the purified membrane protein sample was suspended in ReadyPrep 2-D Rehydration 
buffer 1(Bio-Rad Laboratories, Hercules, CA 94547) containing Bio-lite pH 3-10 buffer (Bio-Rad 
Laboratories, Hercules, CA 94547), to a final volume of 200ul. The protein/rehydration buffer mix was 
then applied to a pH 4-7 (11 cm) immobilised pH gradient (IPG) strip (Bio-Rad Laboratories, Hercules, 
CA 94547) and allowed to rehydrate at room temperature for at least 12 hours. IEF was done under the 
following conditions: 8000 V for 20 min, 8000 V for 2 hours and 8000 V for 40 000 V hours at 21°C 
(Protean IEF cell, Bio-Rad Laboratories, Hercules, CA 94547). After IEF focusing the strips were stored 
at -80ºC until required. 
  
2-Dimensional gel electrophoresis (2-DE) 
Equilibration of IPG strips was done by incubating the strips sequentially in equilibration buffer 
containing DTT (Sigma-Aldrich, Missouri, USA) for 15 minutes and then in equilibration buffer 
containing Idoacetamide (Sigma –Aldrich, Missouri, USA) for 15 minutes at room temperature. After 
equilibration, the IPG strips were placed on top of the 12% 2-D SDS-PAGE gels, and sealed with 0.5% 
agarose (Bio-Rad Laboratories, Hercules, CA 94547). Gel electrophoresis of the second dimension 
separation was done under constant voltage (250 V) for 2-3 hours in cathode and anode buffers. 
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3.3.4. Protein detection using coomassie brilliant blue 
After 2-DE, the proteins were fixed in the gel by incubating in a fixing solution for 1 hour. Protein gels 
were then heated for 2 min in Coomassie solution 1 before overnight incubation. After overnight 
incubation, gels were immersed and heated in Coomassie solution 2 for 2 minutes after which it was 
placed on a shaker for 30 minutes. This was repeated with Coomassie solution 3. The gels were then 
washed in a destaining solution until complete destaining was achieved. The gels were stored in a 25% 
ammonium sulfate solution (Merck, Darmstadt, Germany) at room temperature until further use. 
 
3.3.5. Protein spot identification and comparisons on 2-DE gels 
Coomassie stained gels were digitalized using a GS-800 Calibrated Densitometer (Bio-Rad Laboratories, 
Hercules, CA 94547) and image analysis were done with Quantityone and PDQuest 2-D advanced 2-D 
analysis software (Version 8.0) (Bio-Rad Laboratories, Hercules, CA 94547). All 2-DE experiments were 
repeated at least three times from independent initial cultures to overcome technical and biological 
variation.  
 
Three independent comparative analyses were done on gels generated by 2-DE from the two selected 
strains: (i) High MIC strain (R451) RIF exposed VS High MIC strain (R451) unexposed, (ii) Intermediate 
MIC strain (R439) RIF exposed VS Intermediate (R439) MIC unexposed strain, (iii) High MIC strain 
(R451) RIF exposed VS Intermediate MIC strain (R439) RIF exposed. No comparison between the 
unexposed strains was made, as the aim of this study was to observe the proteomic response of these 
isolates when exposed to RIF.  
 
A Master Image Gel (MIG) was constructed from all triplicate gels and utilized for comparison. All spots 
constantly present on all three gels were included on the master gel and used for quantitative and 
qualitative analysis. Statistical spot-intensity comparison between the two strains between different 
experimental conditions was conducted with a PDQuest integrated T-test with a confidence interval of 
95%. A significant level of p<0.05 was considered as statistically significant. Quantitative (present and 
absent) and qualitative (differentially expressed) analysis was also done visually to refine stringency.  
Spots of interest (spots statistically differentially expressed between the two strains between different 
experimental conditions) were excised with sterile blades from gels and stored in 100µl of double distilled 
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Milli-Q water in a 1.5ml Eppendorf tube (Merck, New Jersey, USA) at room temperature for future Mass 
spectrometric analysis.  
 
3.3.6. Protein identification 
Mass Spectrometry (MS) analysis was done by the Proteomic Research Group at the University of the 
Western Cape. Briefly, excised gel spots were digested with trypsin prior to MALDI-TOF analysis. The 
peptide masses generated with Matrix Assisted Lazer Desorption/Ionization Time of Flight (MALDI-
TOF) analysis were then submitted into the Mascot program (http://www.matrixscience.com). Protein 
MOWSE scores produced by the mascot program greater than 52 were considered as significant. Results 
obtained from MALDI-TOF mass spectrometry were further compared to the whole genome sequence 
comparison of the M. tuberculosis H37Rv reference strain (http://genolist.pasteur.fr/TubercuList) and 
categorized according to function from literature searches (1).  
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3.4. TRANSCRIPTOMICS 
 
3.4.1. RNA Extractions from M. tuberculosis 
After antibiotic exposure, five volumes of 5M GITC (Sigma-Aldrich, St Louis, Germany) were added to 
one volume of each M. tuberculosis culture. The cultures were centrifuged (Eppendorf, Centrifuge 
5810R) in 50 ml tubes (LASEC, South Africa) at 3 000 rpm for 20 minutes at 20 °C. The supernatant was 
discarded and the bacterial pellet was transferred to a 2 ml Eppindorf tube (Merck, New Jersey, USA) and 
centrifuged at 13 000 rpm for 1 minute at room temperature. After centrifugation, the pellet was re-
suspended in 1 ml TRIZOL LS reagent (Invitrogen, CA, USA). The suspension was transferred to a 2 ml 
screw capped tube containing silica beads (IEPSA, Medical diagnostics, South Africa) and ribolysed 
using a FastPrep FP120 ribolyser (Bio101 SAVANT, Vista, USA) at 6 m/s for 3 x 20 seconds with 1 
minute of cooling on ice between intervals. The lysed suspension was centrifuged at 13 000 rpm for 45 
seconds. The supernatant above the beads and cellular debris were transferred to an 2 ml Phase Lock gel 
tube (Merck New Jersey, USA) containing 300µl chloroform: Isoamyl alcohol (24:1) (Sigma-Aldrich, St 
Louis, Germany). The tube was inverted rapidly for 15 seconds, followed with periodically inversion for 
an additional 2 minutes. The tube was incubated for 5 minutes at room temperature and then centrifuged 
at 13 000 rpm for 10 minutes. The top aqueous layer was then transferred to a clean 1.5 ml tube 
containing an equal volume of isopropanol and incubated overnight at -20°C. Precipitated nucleic acids 
were collected by centrifugation at 12 000g for 30 minutes at 4ºC. After centrifugation, the RNA pellet 
was washed with 1 ml 70% ethanol, inverted several times and centrifuged at 12 000 g for 10 minutes at 
4°C.  After centrifugation, the ethanol was aspirated and the RNA pellet was allowed to air-dry at room 
temperature. The RNA pellet was dissolved in 70 µl RNase-free water (Ambion, Applied Biosystems, 
CA, USA) and stored at -80°C for further use.  
 
DNase treatment 
Contaminating chromosomal DNA was digested with RQ1 RNase-free DNase (Promega, WI, USA) 
according the instructions of the manufacturers. In short, 15 µl of RNA was added to 4 µl DNase and 4 µl 
DNase Buffer, followed by incubation for 30 minutes at 37°C. After incubation the DNase treated RNA 
was stored at -80°C for further use. 
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Phenol treatment 
Traces of DNA were further eliminated by adding RNase-free water to the DNase treated sample to a 
final volume of 200 µl. An equal volume of Phenol: Chloroform (4:1) (Sigma-Aldrich, St Louis, 
Germany) was added to the diluted RNA and mixed by gentle inversion. The RNA/Phenol: Chloroform 
mix was incubated for 10 minutes on ice. After incubation, the RNA/Phenol: Chloroform mix was 
centrifuged for 10 minutes at 12 000 rpm at room temperature. The top layer was transferred to a clean 
tube and 1/10 volume of Sodium Acetate (pH 5.2) (Merck, New Jersey, USA) and 2.5 volumes of 100% 
Ethanol (Merck, New Jersey, USA) was added to the RNA. The RNA was incubated for 1 hour (or 
overnight) at -20°C. The precipitated nucleic acids were collected by centrifugation (12000 g for 30 
minutes at 4°C). After centrifugation, the pellet was washed with 1 ml 70% ethanol, inverted several 
times and centrifuged at 12 000 g for 10 minutes at 4°C. After centrifugation, the ethanol was aspirated 
and the purified RNA pellet was allowed to air-dry at room temperature. The RNA pellet was dissolved in 
70 µl of RNase-free water and stored at -80°C till further use. The RNA quality and quantity were 
assessed by using the Experion analyzer with the Experion Software version 2.01 (Bio-Rad Laboratories, 
Hercules, CA 94547).  
 
3.4.2. cDNA Synthesis 
cDNA was synthesized from 1µg highly purified RNA using the QuantiTect Reverse Transcriptase kit 
according to the manufacturer‟s instructions (Southern Cross Biotechnologies). In short, 1µg RNA was 
mixed with 2 µl genomic DNA Whipeout Buffer and RNase-free water (to a volume of 14 µl) and 
incubated for 2 minutes at 42°C. After incubation Quantiscript Reverse Transcriptase, Quantiscript RT 
buffer, and RT Primer Mix was added to the RNA mix and incubated for 15 minutes at 42°C. After 
incubation the mix was incubated for 3 minutes at 95ºC to inactivate the Quantiscript Reverse 
Transcriptase. 
 
3.4.3. Primer design for Quantitative Real Time PCR (QRT-PCR) of candidate genes 
PCR primers (Table 3.2) for quantitative reverse transcriptase analysis of the candidate genes were 
designed against the whole genome sequence of the M. tuberculosis H37Rv reference strain 
(http://genolist.pasteur.fr/TubercuList) using Primer software 3 version 0.2 (Whitehead Scientific, South 
Africa). 
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Table 3.2: Primers used for QRT-PCR 
 
Gene Primer name Primer sequence Product  
Size (bp) 
Tm 
(°C) 
atpA atpA RT Forward: 5‟ ATCCAGAGCGCAATCGAAG 3‟ 
Reverse: 5‟ GGGAATTCGAGCAGCTCTT 3‟ 
150 61 
atpH atpH RT Forward: 5‟ CGCATCGCAGAACAACTAGA 3‟ 
Reverse: 5‟ CTGATCGGCCACGTGATT 3‟ 
182 60 
 
 
3.4.4. Quantitative  REAL-TIME PCR (QRT-PCR) 
Currently two major real time PCR quantification methods are being used, the absolute or relative 
quantitative method (2,4) . Analysis of both methods can either be done using the standard curve method 
or the delta-delta Ct method. The standard curve method for either absolute or relative quantification is 
based on the construction of standard curve of cycle number at a threshold (CT) against initial input 
amount of total RNA or copy number. This method assumes an approximately equal amplification 
efficiency of PCR among the diluted samples of the same gene, thus producing a linear relationship of CT 
against initial input amount of total RNA or copy number. An optimal PCR reaction yields a slope of -3.3 
on the standard curve with an ideal correlation coefficient value -1. Relative quantification using the 
delta-delta CT method is the analytic method of choice for many real-time PCR studies. In this method a 
comparison within a sample (cDNA) is made with the gene of interest to that of a control gene. 
Quantification is done relative to the control gene(s) by subtracting the cycle threshold, or CT, of the 
control gene from the CT of the gene of interest (R=2 
-(∆CT sample -∆CT control)
), and the resulting difference in 
cycle number representing the fold difference of template for these two genes (4).  
 
In this study both the standard curve and delta-delta CT methods were used. The standard curve method 
was used for relative quantification of the reference genes (SigA and 16S). The template concentrations 
were given arbitrary values of 1 (for 10 fold-dilution of synthesized cDNA), 0.1 (for 100 fold dilution), 
0.01(for 1 000 fold dilution) and 0.0001 (for 10 000 fold dilution). A standard curve assay was done for 
each reference gene on both biological and technical duplicate samples. Whereas the delta-delta CT 
method was used for the candidate genes.  
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A standard 20μl PCR reaction was set up by adding 2µl of LightCycler Faststart DNA MasterPLUS SYBR 
Green I reaction mix (Roche Applied Science, Germany), 1 µl forward and reverse primer (10µM) of 
each candidate gene, 14µl of RNase-free water and 2µl of diluted cDNA (1/10 dilution for RIF treated 
samples, ½ dilution for control samples). A negative control was included which contained the same mix 
with the cDNA replaced by water. The PCR mix was subsequently transferred to capillary tubes (Roche 
Applied Science) in a pre-cooled adapter block after which it was transferred to a bench top centrifuge 
and centrifuged at 3rpm for 2 sec. The capillaries were placed into the Lightcycler 2.0 instrument (Roche 
Applied Science) and cycled through a four step PCR parameter protocol: (i) Activation program (95°C 
for 15 minutes); (ii)  RT PCR program repeated for 50 cycles (95°C for 3s for denaturation, 60°C for 15s 
for annealing and 72°C for 6s for polymerase elongation); (ii) Melting curve program (95°C for 0s, 60°C 
for 15s, 90°C for 0s with a heating rate of 0.2°C/s) and (iv) Cooling down program of 40°C for 30s. 
 
Therefore, for each gene a PCR reaction was set up with a 1000 fold dilution of cDNA of each reference 
gene (in duplicate), a two fold dilution of cDNA for control samples (in duplicate) and a 10 fold dilution 
of cDNA for RIF treated samples. Each PCR reaction was set up in for biological and technical duplicate 
samples. 
 
3.4.5. Statistics 
Significant fold changes were identified based on The Relative Expression Software Tool -384 (REST-
384©) that assigns significance with a significance level of 5% (3).  
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3.5. GENOMICS 
A panel of susceptible and resistant isolates from the Beijing (nresistant=5, nsusecptible=5), LAM (nresistant=5, 
nsusecptible=5), and LCC (nresistant=5, nsusecptible=10) strain families were selected to screen for mutations that 
might be present in the candidate genes and in the regions immediate upstream of these genes. 
 
3.5.1. DNA extraction 
Crude DNA was extracted by boiling 500µl aliquot of the glycerol M. tuberculosis stock of each strain in 
a 1.5 ml Eppendorf tube (Merck, New Jersey, USA) for 20 minutes at 100°. These crude DNA templates 
were then stored for subsequent PCR analysis. 
 
3.5.2. Primer design for PCR amplication of candidate genes 
Primer software 3 version 0.2 (Whitehead Scientific, South Africa) and the M. tuberculosis H37Rv 
reference strain (http://genolist.pasteur.fr/TubercuList) were used to design four sets of overlapping PCR 
primers to amplify the complete DNA sequence of each candidate gene, as well as at least 90 base pairs 
upstream from the transcription start site (Figure 3.2; Table 3.3).  
 
 
Figure 3.2: Primer design for candidate genes. For each candidate gene four sets of primers were designed for 
sequence analysis. 
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Table 3.3: Primers used for genomic PCR reactions 
 
Gene Primer 
name 
Product region Primer sequence Product 
Size (bp) 
Tm 
(°C) 
atpA atpA 1 - 91 to 471
a 
Forward: 5‟ ACGCTCTCGTCTCGTCTAGC 3‟ 
Reverse: 5‟ CGTCAATCGCCTTGATCC 3‟ 
562 61 
atpA 2 385 to 922 Forward: 5‟ GAGACGTCGACTCCGATACTC 3‟ 
Reverse: 5‟ CGCGAATGCAGATAGAACAC 3‟ 
537 61 
atpA 3 811 to 1348 Forward: 5‟ TTCGACGACCTGACTAAGCA 3‟ 
Reverse: 5‟ GGAAGATCGAAACCACTTGC 3‟ 
537 61 
atpA 4 1180 to +78
b
  Forward: 5‟ GCTTGGACCTTTCGCAATAC 3‟ 
Reverse: 5‟ GGCCTTGGTGATCTTTTTGA 3‟ 
548 61 
atpH atpH 1 - 131 to 420
c 
Forward: 5‟ AGCAATTGAAGCGGGAGAG 3‟ 
Reverse: 5‟ CTGATCGGCCACGTGATT 3‟ 
551 60 
atpH 2 242 to 778 Forward: 5 „CTGATCGGCCACGTGATT 3‟ 
Reverse: 5‟ GCTTCGATACGGCTGTGC 3‟ 
536 60 
atpH 3 697 to 1220 Forward: 5‟ GCTTCGATACGGCTGTGC 3‟ 
Reverse: 5‟ GTCACGGGGTGACCGTAG 3‟ 
523 60 
atpH 4 1087 to +199
d
  Forward: 5‟ CTGTTCCTGGCCGAAGTTG 3‟ 
Reverse: 5‟ GTCATCACCGATGGCAAAC 3‟ 
453 60 
 
 
 
 
 
3.5.3. PCR Amplification of candidate genes 
DNA amplifications were executed in 25 µl reaction volumes. The PCR master-mix consisted of 5 µl 5X 
Q-solution, 2.5 µl 10X reaction buffer, 2 µl MgCl2 (25mM), 4 µl deoxyribonucleotide triphosphates 
(dNTPs) (0.2mM of each dNTP), 0.5 µl Forward primer (50pM), 0.5 µl Reverse primer (50pM), 0.125 µl 
Hotstar Taq polymerase (5 units/µ)l, 1.25 µl of the crude DNA template, and 7.85 dH2O to make up a 
final volume of 25 µl. The reaction mixtures were heated in the thermal cycler (GeneAmp PCR System 
2400, Applied Biosystems, Foster City, CA, USA) at the following conditions: an initial denaturing step 
at 95ºC for 15 minutes, followed by 35 cycles of denaturation at 94ºC for 1 minute, annealing at Tm 
(62ºC) for 1 minute, extension at 72ºC for 2 minutes, and a final extension step at 72ºC for 15 minutes. 
The primers used for the PCR reactions are tabulated in Table 3.3.  
 
Legend to Table 3.3: 
a  
Product region between 91 nucleotides upstream from transcription start site and 471 nucleotides inside gene  
b 
Product region between 1180 nucleotides inside the structural gene  to 78 nucleotides downstream from coding region
 
c
Product region between 131 nucleotides upstream from transcription start site and 420 nucleotides inside gene 
d
 Product region between 1087 nucleotides inside the structural gene  to 199 nucleotides downstream from coding region 
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A 1.5% Agarose gel was prepared by dissolving 1.5 g Agarose in 100 ml 1x-TBE buffer with 5 µl 
ethidiumbromide. The PCR products were mixed with 5 µl loading dye (0.25% Xylene Cyanol, 30% 
glycerol) and loaded onto the gel. The gel was run at 150 V for approximately 1-2 hours in 1x TBE buffer 
and visualized under ultra violet light using the Kodak Digital Science Electrophoresis Documentation 
and Analysis System 120 (Vilber Lourmat, France). 
 
3.5.4. Sequencing 
PCR products were submitted for PCR clean-up and sequencing at the Central Analytic Facility of 
Stellenbosch University. Sequences were then compared with the whole genome sequence of M. 
tuberculosis H37Rv reference (http://genolist.pasteur.fr/TubercuList) to determine if mutations are 
present in the candidate genes from different M. tuberculosis strain families. 
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3.6. LIST OF BUFFERS AND SOLUTIONS 
 
PCR BUFFERS 
 
10X TE Buffer:    10mM Tris  
      1mM EDTA  
      dH2O 
 
10X TBE Buffer (pH 8.3):   0.45M Tris (108g) 
      0.44M Boric acid (55g) 
      10mM EDTA (7.4g) 
      dH2O to make up 1L 
 
CULTIVATION OF M. TUBERCULOSIS STRAINS 
 
Middlebrook 7H9 medium:    7H9 medium (4.7g) 
      dH2O (900ml) 
      Glycerol (2ml) 
      Polysorbate (Tween80) (0.5ml) 
 
ADC:      BSA (25g) 
      Glucose (10g) 
      Catalase (0.75ml) 
      dH2O to make up 500ml 
 
EXTRACTION OF WCL PROTEINS 
 
Lysis buffer:     0.5M Tris-HCl (Sigma-Aldrich, Missouri, USA) (5ml) 
      Triton X-114 (1ml) 
10mM PMSF (1.74mg PMSF/1ml isopropanol)  (5ml) 
2 Protease inhibitor cocktail tablets (Roche  Applied 
Science , Germany ) 
      dH2O to make up 50 ml 
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PBS (pH 7.3):     NaCl (8g) 
      KCI (0.2g) 
      diNaHPO4 (1.15g) 
      KH2PO4 (0.2g) 
      1% Tween80 
      dH2O to make 1L 
 
 
2-D GEL ELECTROPHORESIS SOLUTIONS 
 
Equilibration buffer 1:  0.375M Tris-HCl (pH 8.8) 
      6M Urea 
      30% Glycerol (Sigma-Aldrich, Missouri, USA) 
      2% SDS 
      2% DTT 
 
Equilibration buffer 2: 0.375M Tris-HCl (pH 8.8) (Sigma-Aldrich, Missouri, 
USA) 
      6M Urea 
      30% Glycerol (Sigma-Aldrich, Missouri, USA) 
      2% SDS 
      1 g Iodoacetamide 
 
Cathode buffer: 192M Glycine (pH 8.3) (Sigma-Aldrich, Missouri, USA) 
      pH with Tris (Sigma-Aldrich, Missouri, USA) 
      add 0.1% SDS 
      miliQH2O to make 1L 
 
Anode buffer: 0.375M Tris (pH 8.8) (Sigma-Aldrich, Missouri, USA) 
      pH with AcOH (Merck, Darmstadt, Germany) 
      miliQH2O to make up 1.5L 
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Fixing buffer:     50% MeOH (Merck, Darmstadt, Germany) 
      5% AcOH (Merck, Darmstadt, Germany) 
Coomassie I: 0.025% (w/v) Coomassie Brilliant Blue R-250 (Sigma-
Aldrich, Missouri, USA) 
25% (v/v) isopropanol (Merck, Darmstadt, Germany) 
      10% (v/v) acetic acid (Merck, Darmstadt, Germany) 
 
Coomassie II: 0.003% (w/v) Coomassie Brilliant Blue R-250 (Sigma-
Aldrich, Missouri, USA) 
10% (v/v) isopropanol (Merck, Darmstadt, Germany) 
      10% (v/v) acetic acid (Merck, Darmstadt, Germany) 
 
Coomassie III:  0.003% (w/v) Coomassie Brilliant Blue (R-250) (Sigma-
Aldrich, Missouri, USA) 
      10% (v/v) acetic acid (Merck, Darmstadt, Germany) 
 
Destaining:     10% (v/v) acetic acid (Merck, Darmstadt, Germany) 
 1% (v/v) glycerol (Sigma-Aldrich, Missouri, USA) 
 
EXTRACTION OF RNA 
 
5M GITC: Guadinine thiocyanate (295.4 g) (Sigma-Aldrich, 
Missouri, USA) 
Sodium N-Lauroyl Sarcosine (2.5 g) (Sigma-Aldrich, 
Missouri, USA) 
β-mercapto ethanol (3.5ml) (Sigma-Aldrich, Missouri, 
USA) 
12.5 M Sodium citrate pH 7.0 (Sigma-Aldrich, Missouri, 
USA) 
      Tween80 (5 ml) (Sigma-Aldrich, Missouri, USA) 
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CHAPTER 4 
RESULTS 
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4.1. PROTEOMICS 
Three comparative experiments using PD-Quest Advanced 2-D analysis software (Version 8.0) (Bio-Rad 
Laboratories, Hercules, CA 94547) were done to determine the global membrane protein expression 
profile of M. tuberculosis clinical strains after RIF exposure at the critical concentration (2μg/ml) for 24 
hours. Biological and technical replicas were done for each experiment. In experiment 1 (Figure 4.1) and 
2 (Figure 4.2), RIF exposed strains with a high MIC (R451) and intermediate MIC (R439) was compared 
to the RIF unexposed control group of R451 and R439 respectively. In the third experiment (Figure 4.3) a 
comparative analysis was done between the High MIC (R451) and intermediate MIC (R439) strains when 
exposed to RIF.  Figures 4.1, 4.2, 4.3 show the electrophoretic profiles of proteins seperated with 2-DE.  
 
All proteins were separated on a 12% polyacrylamide gel with a pI range of 4-7 and a molecular weight 
of 10-75kDa. Statistical analysis was done by using a PD Quest (Version 8.0) (Bio-Rad Laboratories, 
Hercules, CA 94547) integrated statistical analysis tool (T-test) with a confidence interval of 95% (p-
value of <0.05). Arbitrary density values were assigned by PD Quest to each differentially expressed spot. 
Differentially expressed spots between the experimental conditions were expressed as a ratio of the test 
versus the control when one of the two was set as 1. 
 
4.1.1.  Experiment 1: High MIC strain (R451): RIF exposed vs. unexposed 
PD Quest analysis identified 220 protein spots of which 86 were significantly differentially expressed 
(p=0.05) between the RIF exposed and unexposed conditions. From the 86 spots (Table 4.1), 64 were 
unique to RIF exposed gels, 6 spots were unique for the unexposed gels and 16 were present in both RIF 
exposed and unexposed gels. From these 16 spots, 7 were up regulated in the unexposed condition and 9 
were up regulated in the exposed condition. These 86 protein spots were also visually inspected to refine 
the analysis before 20 spots were excised from the gel and submitted for mass spectrometry.  
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Figure 4.1: Two dimensional electrophoresis patterns of membrane proteins from a M. tuberculosis high RIF MIC DRF 150 
strain (R451). (A) Exposed to 2µg/ml Rifampicin and (B) unexposed. Proteins were stained with Coomassie brilliant blue. 
Molecular mass range (in kilodaltons) and pI range (between 4 and 7) are indicated. Circled spots were excised and submitted 
for mass spectrometry analysis 
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Spots               
SSP 
nr Unexposed
 
RIF 
exposed Ratio 
SSP 
nr Unexposed 
RIF 
exposed Ratio 
101 - 39.9 19.31 4604 - 13.5 6.52 
401 - 15.9 7.67 4902 34.7 23.4 0.67 
402 - 27.4 13.26 4905 - 8.5 4.09 
403 10.2 - 0.07 5202 - 14.7 7.13 
501 33.1 4.8 0.14 5301 - 16.2 7.83 
502 - 24.5 11.88 5302 - 8.6 4.18 
503 - 20.4 9.87 5402 - 10.5 5.08 
504 26.8 19.6 0.73 5601 - 8.6 4.14 
505 - 11 5.32 5602 - 9.9 4.81 
1202 28.4 22.8 0.8 5902 - 18.4 8.91 
1203 68 116.7 1.72 5905 - 27.1 13.13 
1301 - 23.2 11.22 6101 - 8.4 4.08 
1501 21.3 45.3 2.13 6202 - 16.1 7.79 
1502 34.2 55.8 1.63 6203 - 11.3 5.48 
1701 - 8.3 4.02 6301 - 44.2 21.41 
2001 135.8 107 0.79 6401 - 7.1 3.46 
2002 - 52.2 25.25 6402 - 9 4.38 
2005 139 - 0.01 6901 - 23.7 11.45 
2401 18.1 25.3 1.39 6902 - 11.9 5.74 
2402 - 17.7 8.55 7001 23.7 32.7 1.38 
2404 - 48.9 23.67 7301 - 8.7 4.22 
2501 - 14.3 6.93 7401 - 6.2 2.99 
2601 19.7 26.4 1.34 7402 - 10.5 5.08 
2702 - 12.8 6.2 7403 - 12.1 5.85 
2901 - 31.7 15.34 7404 - 22.3 10.77 
2902 - 7.3 3.54 7405 - 28.3 13.69 
3001 - 42.4 20.52 7501 - 16.8 8.13 
3101 - 30.3 14.67 7503 - 28.3 13.68 
3201 - 19.8 9.61 7602 - 11.8 5.71 
3601 66.2 54.9 0.83 7606 - 44 21.32 
3603 60.4 77.2 1.28 7608 - 22 10.66 
3701 - 12.9 6.26 7901 - 12.4 6.01 
3703 - 26.9 13 8104 - 28 13.55 
3906 149.6 - 0 8205 59.4 - 0.01 
4101 27 30.6 1.13 8305 - 51.1 24.75 
4102 - 22.6 10.93 8307 - 22.4 10.82 
4103 - 26.7 12.93 8310 43.5 121.1 2.78 
4302 24.9 - 0.03 8501 - 13.9 6.74 
4401 22.3 18.9 0.85 8601 - 88.8 42.99 
4402 - 11.6 5.6 8603 - 194.2 94.03 
4502 - 18.3 8.86 9102 - 30.7 14.85 
4601 - 15.3 7.42 9103 - 17.7 8.55 
4602 - 11.3 5.46 9105 29 - 0.03 
 
 
Legend to table 4.1: 
SSP number = number assigned to protein spots by PD Quest software  
Arbitrary density values were assigned by PD Quest software to each differentially expressed spot 
- = absent protein spot, highlighted spots were submitted for mass spectrometry analysis 
 
Table 4.1: Differentially expressed protein spots between RIF exposed and unexposed 
high MIC strain (R451) 
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MASS  SPECTROMETRY ANALYSIS  
In total 21 proteins were identified from the 20 spots submitted for mass spectrometry. Spots 3101 and 
6301 were each identified as a mixture of two unique proteins. No positive identification for spot 2402 
could be made due to insignificant MOWSE scores. Table 4.2 depict the electrophoretic characteristics 
and matched peptides of the identified spots.  
 
Table 4.2: Electrophoretic characteristics and matched peptides of identified spots from Experiment 1 
Spot nr Predicted 
MW 
(kDa) 
pI Matched peptides 
Position start/end sequence 
MOWSE 
Score * 
Queries 
Matched 
Coverage 
% 
ψ 
1203 28064 4.66 10-72/ QVPDTWSERKLTDGDFTLDREAADAVLDEINERAVE 
EALQIREKEAADGIE GSVTVLTAGP ER 
88-110/ AVHLKDDGMHGSDVIQTGWALAR 
161-197 ITGERETDEGVFTLEATLPAVISVNEKINEPRFPSFK 
241-264/ TAGEKVTDEGEGGNQIVQYLVAQK 
192 15 55 
2402 No positive Identification 
3001 20429 4.73 1-8/ MTEYEGPK 
47-100/ HFYSQAVEERNHAMMLVQHLLDRDLRVEIPGVDT 
VRNQFDRPREALALALDQER 
149-171/ AGANLFELENFVAREVDVAPAASGAPHAAGGRL 
145 10 52 
3101
§
 56561 
 
4.85 
 
1-12/ AKTIAYDEEA RR 
17-26/ GLNALADAVK 
41-56/ KWGAPTITNDGVSIAK 
78-99/ KTDDVAGDGTTTATVLAQALVR 
195-207/ GYISGYFVTDPER 
320-342/ VVVTKDETTIVEGAGDTDAIA GR 
348-361/ QEIENSDSDYDREK 
378-397/ AGAATEVELKERKHRIEDAVR 
449-464/ QI/AFNSGLEPGVVAEK 
205 23 27 
27529 4.84 2-29/ MADPGPFVAD LRAESDDLDALVAHLPADR 
104-117/ GRLHEELLAVPDGR 
172-255/ DYAFIVNNLTPPAEPFLVELRGPSGDTWSWGPSDA 
AQRVTGSAEDFCFLVTQRRALSTLDVNAVGEDAQRWLTIA 
QAFAGPPGR 
49 
3201 30046 4.97 55-63/ DIVWEQVQR 
102-110/ RDIGGVMVR 
117-125/ GDRHVIAAR 
189-226/ VYAEIVGNPTGWVEIVASQRHPG GTTTQTDAAAG 
VLDSK 
236-281/ RVGGDLYGSFLPGTQQNLERALDGLLELLPAGAW 
LDHTSDHAQASSR 
59 8 39 
4102 27256 4.93 2-10/ TYETILVER 
134-145/ LGVLPGM GGSQR 
155-163/ AMDLILTGR 
179-205/ VVPADDLLTEARATATTISQMSASAAR 
214-227/ AFESSLSEGLLYER 
200-257/ AAPQFTHR 
66 7 30 
4103 20113 5.02 1-13/ MRVLLLGPPGAGK 
24-36/ LGIPQISTGELFR 
52-88/ LDAGDLVPSDLTNELVDDRLNNPDAANGFILDGYPR 
95-123/ ALHEMLERRGTDIDAVLEFRVSEEVLLER 
128-140/ GRADDTDDVILNR 
143-156/ VYRDETAPLLEYYR 
161-174/ TVDAVGTMDEVFAR 
114 13 73 
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4502 42628 4.92 2-11/ PEAVIVSTAR 
71-88/ VVAVALGYDFLPGTTVNR 
105-122/AGEGDAFISAGVETVSR 
126-160/ GNSDSWPDTKNPLFDGAQERSAAAAAGADEWHD 
PR 
188-239/ EEQDRWGVRSQNRAEEAIKNGFF EREITPVTLPDG 
TTVSTDDGPRPGTTYEK 
276-286/ AKELGLTPLAR 
315-390/AGMAITDIDLVEINEAFAVQVLGSAR 
103 11 41 
5202 30294 5.17 70-86/ V GTFNPAALLH GSQGIR 
152-182/ GERPAAPEFPDRHPDARID MLTREDQALIYR 
220-239/ ALVAELGGGVAANITSIAAR 
266-278/TEVAGSDGAEAR 
78 5 27 
5302 32910 5.12 1-15/ MRPALSDYQHVASGK 
18-51/ EIYRVDDEHLLLVASDRISAYDYVLDSTIPDKGR 
104-119/ GYLTGSGLLDYQATGK 
135-145/ FATPLFTPATK 
176-274/TLQTYVQAADHALTRGIIIADTKFE FGIDRHGNLLL 
ADEIFTPDSSRYWPADDYRAGVVQTSFDKQFVRSWLTGSE 
SGWDRGSDRPPPPLPEHIVEATR 
277-297/ YINAYERISELKFDDWIGPGA 
160 17 65 
5601 43345 4.93 1-9/  MELLRGALR 
77-86/ FGDVLPFLVK 
115-149/ IPVSSPVRNYRDTSKPELLVALQPFEALAGFR 
160-183/ ALAVSDLDPFIDLLSEGSDADGLR 
231-283/ YPGDAGVLAALLLNRISLAPGEAIFLPAGNLHAYV 
RGFGVEVMANSDNVLR 
290-307/ HVDVPELLRVLDFAPTPK 
379-392/ GTAAWVAADDGPIR 
96 12 39 
5602 56561 4.85 1-12/ AKTIAYDEEARR 
33-56/ GRNVVLEKKWGAPTITNDGVSIAK 
78-99/ KTDDVAGDGTTTATVLAQALVR 
104-115/ NVAAGANPLGLK 
195-207/GYISGYFVTDPER 
320-342/ VVVTKDETTIVEGAGDTDAIAGR 
348-361/ QEIENSDSDYDREK 
378-398/ AGAATEVELKERKHRIEDAVR 
428-440/ LEGDEATGANIVK 
94 15 28 
5905 59252 5.03 93-121/ RTGEVLSVPVGDGFLGRVVNPLGQPIDGR 
130-154/ RALELQAPSVVHRQGVKEPLQTGIK 
168-175/ QLIIGDRK 
295-307/ EAYPGDVFYLHSR 
315-333/ LSDDLGGGSLTGLPIIETK 
395-418/ LDLSQYRELEAFAAFASDLDAASK 
466-491/ RFETELLDHMRASEEEILTEIRDSQK 
120 14 26 
6301 
§
 34638 
 
5.11 2-21/ TSQGDTTSGTQLKPPVEAVR 
113-122/ AMFDEVDSPR 
128-178/ IQGWEEFDEPVDRIVSLGAFEHFADGAGDAGFERY 
DTFFKKFYNLTPDDGR 
209-219/ FILTEIFPGGR 
223-237/ ISQVDYYSSNAGWK 
270-282/ GQETYDIYMHYLR 
123 17 39 
28737 2-11/ ANFTAADVKR 
25-42/ NALAETDGDFDKAVEALR 
128-135/ IGEKLELR 
137-150/ VAIFDGTVEAYLHR 
167-184/ GDDAAAAHAVALQIAALR 
187-202/ YLSRDDVPEDIVASER 
203-210/ RIAEETAR 
 
6402 32697 5.2 69-77/ GDPYADRPR 
84-96/ VGADAGAGEFVVLR 
144-159/ RITDATNAIDPLSAIK 
162-176/ LAGYGAGDTDLAWSR 
206-220/ TEPALDVLAGWLASR2 
228-270/ AVGELKVELVRNSETIVLSRPQEGITATLTRTGKPD 
ALVPLAR 
66 8 36 
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6901 59252 5.03 93-121/ RTGEVLSVPVGDGFLGRVVNPLGQPIDGR 
130-151/ RALELQAPSVVHRQGVKEPLQTGIK 
295-307/ EAYPGDVFYLHSR 
315-333/ LSDDLGGGSLTGLPIIETK 
465-491/ RFETELLDHMRASEEEILTEIRDSQK 
74 11 20 
7404 40815 5.2 59-63/ DAKQELIDSLEEAVR 
75-99/ ALIATGEQVLVNEHLIGPPPATVIR 
116-132/ RPTYVFAAVDHTGADVK 
187-215/ LVDAADPEVVFVSGEVRSRTDLLSTLPQR 
220-247/ VSQLHAGPRKSALDEEEIWDLTSAEFTR 
250-266/ YAEITNVAQQFEAEIGR 
329-347/ AD EALPFAAIAVGAALVR 
351-368/ IAPLDGVGALLRYAATNR 
103 11 44 
6401 35538 4.95 3-23/ TPATVVAGVDLGDAVFAAAVR 
29-38/ VEQLMDTELR 
164-177/ GTSENVDSIEQYLK 
93-207/ LGGMFSGATDEQVER 
268-281/ ALLNGPVDDDAEVR 
296-243/ AKDVLAQYAAQARHELALLPDVPGRRALAALVD 
YTVSR 
80 9 33 
7405 36536 5.28 21-57/ APSLHNSQPWRWIAEDHTVALFLDKDRVLYATDHSG 
R 
72-85/ VAMAAAGTTANVER 
112-191/ LRADAILLRRTDRLPFAEPPDWDLVESQLR 
151-167/ IDVIADDMRPELAAASK 
215-245/ DFPVVANTDRRPEFGHDRSKVLVLSTYDNER 
283-326/ DLVAALIGQPATPQALVRVGLAPEMEEPPPATPRR 
PIDEVFHVR 
166 17 52 
8603 43566 5.28 9-25/ TKPHVNIGTIGH VDHGK 
35-59/ VLHDKF PDLNETKAFDQIDNAPEER 
62-92/GITINIAHVYQTDKRHYAHVDAPGHADYIK 
140-173/ ADAVDDEELLELVEMEVRELL AAQEFDEDAPVVR 
236-282/GVINVNEEVEIVGIRPSTTKTTVTG 
VEMFRKLLDQGQAGDNVGLLLR 
365-376/ LIQPVAMDEGLR 
95 12 41 
 
 
 
4.1.2. Experiment 2: Intermediate MIC strain (R439): RIF exposed vs. unexposed 
PD Quest analysis identified 231protein spots of which 53 were differentially expressed (p=0.05) between 
the RIF exposed and unexposed conditions. From the 53 spots (Table 4.3), 11 were unique for the 
exposed condition, 20 were unique for the unexposed condition and 22 were present in both the RIF 
exposed and unexposed gels. From these 22 spots, 5 were up regulated in the unexposed condition and 17 
were up regulated in the exposed condition. When visually inspected, none of the spots described in Table 
4.3 were observed as differentially expressed and therefore none were picked and excised for mass 
spectrometry. These results could not be due to experimental error since cultivation, RIF exposure, 
protein extractions and 2-DE gels were done in biological and technical replicas. 
 
Legend for table 4.2: 
* According to Mascot results, Protein MOWSE scores greater than 52 were considered as signifcant. 
§ Spots were found to be a mixture of two or more proteins, each described in a row of the table 
Ψ Percentage of protein sequence covered with identified peptides 
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Figure 4.2: Two dimensional electrophoresis patterns of membrane proteins from a M. tuberculosis 
intermediate RIF MIC DRF 150 strain (R439). (A) Exposed to 2µg/ml RIF and (B) unexposed. Proteins 
were stained with Coomassie brilliant blue. Molecular mass range (in kilo daltons) and pI range (between 4 
and 7) are indicated.  
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Table 4.3: Differentially expressed protein spots between Intermediate MIC strain (R439) RIF exposed 
and unexposed. 
Spots  
SSP nr Unexposed 
RIF 
exposed Ratio SSP nr Unexposed 
RIF 
exposed Ratio 
1102 58.1 115.1 1.98 4506 28.9 17.8 0.61 
1202 12.4 19.4 1.56 5003 328.3 - 0.01 
2101 42.9 315.5 7.35 5201 39.2 56.6 1.44 
2102 175.1 - 0.02 5503 14.1 10.7 0.76 
2104 432.9 216.4 0.5 5505 67.2 - 0.05 
2203 17.8 - 0.18 5506 - 14.5 15.38 
2205 17.4 32.3 1.85 6201 24.6 - 0.13 
2206 - 34.5 36.58 6203 18 28.4 1.58 
2207 - 8.9 9.43 6301 18.8 - 0.17 
2405 18.4 39 2.12 6308 - 9.2 9.76 
3003 - 74.4 78.8 6404 15 - 0.22 
3101 93.4 118.9 1.27 6504 35.6 - 0.09 
3103 131.8 193.4 1.47 7104 29.9 - 0.11 
3106 10.3 - 0.32 7106 - 15 15.92 
3205 13.4 19.9 1.49 7202 25.8 37.8 1.46 
3302 30 - 0.11 7406 10.4 11.7 1.13 
3403 18.8 32 1.7 7501 92.1 56.8 0.62 
3501 20.4 25.2 1.23 7507 132.1 67.9 0.51 
3702 81.8 122.1 1.49 8101 25.8 36.3 1.41 
3705 - 69.5 73.7 8201 41.1 - 0.08 
4102 532.8 457.1 0.86 8202 11.8 - 0.28 
4106 - 346.2 366.87 8204 22 - 0.15 
4107 - 51.8 54.93 8401 9.3 - 0.35 
4108 - 38.8 41.12 9101 18.8 - 0.17 
4202 76.9 106.3 1.38 9106 43.4 - 0.08 
4303 9.4 - 0.35 9112 - 31.8 33.66 
4401 12.3 - 0.27 9202 26.5 - 0.12 
 
 
 
4.1.3. Experiment 3: High MIC strain (R451) RIF exposed vs. Intermediate MIC strain (R439) 
RIF exposed 
PD-Quest analysis identified 283 protein spots of which 116 were differentially expressed (p=0.05) 
between the two strains exposed to RIF. From the 116 spots (Table 4.5), 60 were unique for the high MIC 
strain, 16 were unique for the intermediate MIC strain and 40 were present in both strains when exposed 
to RIF. From these 40 spots, when compared to the intermediated MIC strain, 19 spots were more 
Legend to Table 4.3 
SSP number = number assigned to protein spots by PD Quest software, - = absent protein spot 
Arbitrary density values were assigned by PD Quest software to each differentially expressed spot 
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expressed in the high MIC strain and 21 spots were less expressed in the high MIC strain.  These 116 
spots were also visually inspected to refine the analysis before 20 spots were excised from the gels and 
submitted for mass spectrometry. Five (Table 4.5) of these 20 spots were excised based on differences 
observed during visual inspection of the gels.  
 
Table 4.4: Differentially expressed protein spots between high MIC strain (R451) exposed to RIF and 
Intermediate MIC strain (R439) exposed to RIF 
Figure 4.3: Two dimensional electrophoresis patterns of membrane proteins from M. tuberculosis DRF 150 RIF 
resistant strains. (A) High RIF MIC strain (R451) exposed to 2µg/ml Rifampicin and (B) Intermediate RIF MIC strain 
(R439) exposed to 2µg/ml. Proteins were stained with Coomassie brilliant blue. Molecular mass range (in kilodaltons) 
and pI range (between 4 and 7) are indicated. Circled spots were submitted for mass spectrometry analysis 
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Spots  
SSP 
Low 
MIC 
High 
MIC Ratio SSP 
Low 
MIC 
High 
MIC Ratio 
2002   27 57.73 5606   13.1 28.05 
2303 6.4   0.07 6201 63.1 29.8 0.47 
2304   20.7 44.44 6203 14.8 18.9 1.27 
2305   18.8 40.34 6205   32 68.48 
2403 19.8 14.8 0.75 6206   9.3 19.96 
2409   1.4 3.06 6207   7.6 16.31 
3001   52.9 113.33 6208   5 10.62 
3104 123.4 91 0.74 6209   3.4 7.31 
3105 16.2   0.03 6302 35.7 8.5 0.24 
3107 16.1   0.03 6303   13.3 28.44 
3108   12.6 27 6304   12 25.63 
3201 24.2 17.5 0.72 6305   6.1 13.13 
3203 89.8 94.1 1.05 6306   6.7 14.43 
3204 101.4 80.4 0.79 6307   5.6 12.02 
3306   19.2 41.19 6308   4.5 9.73 
3307 25 51.5 2.06 6309   3.7 8 
3401 12.7 43.7 3.45 6311   3.1 6.69 
3501 14.4   0.03 6315 5.8   0.08 
3502 20.3   0.02 6401 26.7 9.4 0.35 
3503 16.1   0.03 6402 13.2 18.9 1.43 
3504 19.8   0.02 6404 31 19.4 0.63 
3603 10 4.1 0.41 6405 46.4 30 0.65 
3604 10.4   0.05 6406   5.9 12.53 
3605 5.2   0.09 6503   7.7 16.46 
3606   26.5 56.85 6602 51.3 71.4 1.39 
3705   5.5 11.83 6604 22.1 6.6 0.3 
4001 67.2   0.01 6605 24.4 52.3 2.14 
4108 8.1 19.6 2.43 6606 30.7 40.5 1.32 
4202 21.1   0.02 6608   15 32.18 
4205   22.8 48.77 7102 29.4   0.02 
4206   16 34.35 7103   27 57.75 
4302 8.7 12 1.37 7104   15.6 33.42 
4304 5.3 19.9 3.78 7201 30.6 43.7 1.43 
4306   14.6 31.2 7206 34   0.01 
4308   7 14.91 7208 115.9 177.4 1.53 
4503 15.5   0.03 7209   60.3 129.2 
4504 70.8 27.3 0.39 7210   29.3 62.69 
4505 51.3 50.2 0.98 7211   5.2 11.07 
4507 13   0.04 7212   97.7 209.24 
4508 82.5 72.2 0.88 7402 55.3 18.3 0.33 
4509   6.7 14.25 7405   71.7 153.63 
4510   10.7 23.01 7406 14.1 56 3.98 
4603 37.9 7.1 0.19 7407 79.8 146.7 1.84 
4606 2.1 3.8 1.82 7409   19.5 41.87 
4607   288.2 617.26 7410   15 32.1 
4608   24.8 53.03 7411   13.2 28.36 
Table 4.4: Differentially expressed protein spots between high MIC strain (R451) 
exposed to RIF and Intermediate MIC strain (R439) exposed to RIF 
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4701 132.9 88 0.66 7412   1.8 3.77 
5102 15.1 26.2 1.74 7413   15.6 33.49 
5103   13.7 29.35 7501   3.4 7.29 
5203   18.8 40.2 7601   8.5 18.12 
5301 3.6 13.4 3.76 8103   23.5 50.33 
5501 40.7 12.3 0.3 8104   18.3 39.26 
5502 14.2 7.5 0.53 8203   12 25.61 
5503 9 16.9 1.89 8302   18 38.53 
5505 11.4 7.2 0.63 8303   14.3 30.72 
5506   6 12.75 8502 14.9 3 0.2 
5507   2.3 4.93 9105   17.6 37.61 
5604 26.1 53.6 2.05 9106   14 30.09 
5605   78.8 168.88         
 
 
 
Table 4.5: Differential expressed protein spots between high MIC strain (R451) exposed to RIF and 
Intermediate MIC strain (R439) exposed to RIF observed with visual inspection. 
Spot nr High MIC strain RIF exposed Intermediate MIC strain RIF exposed Differential expression 
01 Present Present Up regulated in High MIC 
02 Present Absent  
03 Absent Present  
04 Absent Present  
4608 Present Present Up regulated in High MIC 
 
 
MASS  SPECTROMETRY ANALYSIS  
In total 20 proteins were identified from the 20 spots submitted for mass spectrometry. Spots 4608, 5203, 
6205 and 7405 were each identified as a mixture of two or more unique proteins. No positive 
identification for spot 02, 3105, 6311, 7104 and 9105 could be made due to insignificant MOWSE scores. 
Table 4.6 depict the electrophoretic characteristics and matched peptides of the identified spots.   
Legend for Table 4.4: 
SSP number = number assigned to protein spots by PD Quest software, - = absent protein spot, highlighted spots 
were send for mass spectrometry analysis 
Arbitrary density values were assigned by PD Quest software to each differentially expressed spot 
 
 
70 
 
  
Spot 
nr 
Predicted 
MW 
pI Matched peptides 
Position start/end sequence 
MOWSE 
Score* 
Queries 
Matched 
Coverage 
%
ψ 
1 23525 4.99 14-40/ YILPSFIEHSSFGVKESNPYNKLFEER 
132-159/ VLIHQPSLSGVIQGQFSDLEIQAAEIER 
162-180/ TLMETTLARHTGKDAGVIR 
188-207/ ILTAEEAKDYGIIDTVLEYR 
86 7 43 
02 No positive Identification 
03 17896 5.49 5- 25/ VGDTVVYPHHGAALVEAIETR 
39-87/ VAQGDLTVRVPAENAEYVGVRDVVGQEGLDKVFQVLRAP 
HTEEPTNWSR 
150- 162/ AETILDEVLAAAS 
84 8 51 
04 365522 5.49 2-17/ PIATPEVYAEMLGQAK 
40-85/ 
GFADAGSDGIIQFSTGGAEFGSGLGVKDMVTGAVALAEFTH 
VIAAK 
100-116/ DKLDSYVRPLLAISAQR 
156-179/ IILEI EIGVVGGEEDGVANEINEK 
202-267/ 
YLLAATFGNVHGVYKPGNVKLRPDILAQGQQVAAAKLG 
PADAKPFDFVFHGGSGSLKSEIEEALR 
319-340/ KAEASMSQRVVQACNDLHCAGK 
87 14 55 
3105 No positive Identification 
3107 30286 4.65 64-86/YPGGVVMAGDRRSTQGNMISGR 
90-146/ 
KVYITDDYTATGIAGTAAVAVEFARLYAVELEHYEKLEGV 
PLTFAGK 
177-204/ IVSFDAAGGWNIEEEGYQAVGSGSLFAK 
209-266/ 
KLYSQVTDGDSGLRVAVEALYDAADDDSATGGPDLVRG 
IFPTAVIIDADGAVDVPESR 
126 14 53 
4108 23525 4.99 14-38/ YILPSFIEHSSFGVK 
132-159/ VLIHQPSLSGVIQGQFSDLEIQAAEIER 
162-170/ TLMETTLAR 
188-207/ ILTAEEAKDYGIIDTVLEYR 
59 5 33 
4608
§
 56561 
 
4.85 
 
3-12/ TIAYDEEARR 
41-66/ KWGAPTITNDGVSIAKEIELEDPYEK 
78-99/ KTDDVAGDGTTTATVLAQALVR 
104-166/ NVAAGANPLGLKR 
140-
223/EQIAATAAISAGDQSIGDLIAEAMDKVGNEGVITVEESNTF 
GLQLELTEGMRFDKGYISGYFVTDPERQEAVLEDPYILLVSSK 
229-236/ DLLPLLEK 
320-342/ VVVTKDETTIVEGAGDTDAIAGR 
348- 361/ QEIENSDSDYDREK 
391-398/ HRIEDAVR 
402-440/ AAVEEGIVA 
GGGVTLLQAAPTLDELKLEGDEATGANIVK 
449-464/ QIAFNSGLEPGVVAEK 
467-494/ NLPAGHGLNAQTGVYEDLLAAGVADPVK 
497-523/ SALQNAASIAGLFLTTEAVVADKPEK 
313 41 58 
 
62203 4.91 20-37/ HTLSQLRLHELLVEVQDR 
70-82/ AIVHSATSLVDAR 
95-110/ VLHFVYEGIDEETVRR 
117-132/ GLGVIGLLIEDPKP LR 
212-237/ QSWIEATRDIATELLSGTEPATVFR 
287-305/TIPVAGAVLREVFVNGIPR 
310-330/VDLEGLDELADAGPALLLPLR 
378-387/ MRELDVLTDR 
393-401/ DLHDHVIQR 
425-455/ LSDVVDDLQDVIQEIRTTIYDLHGASQGITR 
460-498/ 
IDAAVAQFADSGLRTSVQFVGPLSVVDSALADQAEAVVR 
517-547/ VKVDDDLCIEVTDNGRGLPDEFTGSGLTNLR 
46 
Table 4.6: Electrophoretic characteristics and matched peptides of identified spots from Experiment 3 
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550-571/ AEQAGGEFTLASVPGASGTVLR 
5102 23525 4.99 14-28/ YILPSFIEHSSFGVK 
132-159/ VLIHQPSLSGVIQGQFSDLEIQAAEIER 
162-170/ TLMETTLAR 
188-207/ ILTAEEAKDYGIIDTVLEYR 
57 5 33 
5203 
§
 25964 
 
5.21 
 
26-51/ EIADALLAALERRHEVADAIVEAANK 
159-201/ 
RVDDEEAAWFVAVDSGVKVGMVFGELVHGEVDVRIWIH 
PDHRK 
203-211/ GYGTAALRK 
229-232/ APAAQPAQPGSAGR 
88 18 38 
28879 5.08 32-41/ EASVSLSEIK 
70-97/ RASPSAGALATIADPAKLAQAYQDGGAR 
107-119/ RFQGSLDDLDAVR 
129-142/KDFVVQPYQIHEAR 
168-187/ TESLGMIALVEVHTEQEADR 
30 
5606 56561 4.85 3-12/ TIAYDEEARR 
17-26/ GLNALADAVK 
41-66/  KWGAPTITNDGVSIAKEIEL EDPYEK 
78-99/ KTD DVAGDGTTTA TVLAQALVR 
104-115/NVAAGAN PLGLK 
166-191/VGNEG VITVEESNTF GLQLELTEGM R 
195-223/GYISGYFVTDPERQEA VLEDPYILLV SSK 
320-342/V VVTKDETTIV EGAGDTDAIA GR 
348-361/QEIENSDSDYDRE K 
390-398/HRIEDAVR 
449-464/ QIAFNSGLEPGV VAEK 
367-494/ NLPA GHGLNAQTGV YEDLLAAGVA DPVK 
498-523/ SALQNAASIAGLF LTTEAVVADK PEK 
158 20 46 
6205 
§
 34284 
 
5.10 
 
2-14/ SAMRTHDDT WDIK 
69-84/ AA AIDAETAAIV AYLR 
91-119/ TNFFDTYFASAVAAGIRQVV ILASGLDSR 
123-138/ LDWPAGTI VYEIDQPK 
160-174/E VPADLRQDWP AALR 
203-229/ LFTQVGAV SVAGSRIAAE TAPVHGEER 
263-275/ ASVADWLT DHGWR 
64 19 41 
30277 5.17 70-113/ V GTFNPAALLH GSQGIRLHAP 
LPAAGKLSVVTEVADIQDKG EGK 
152-182/ GERPAAPEF PDRHPDARID MPTREDQALI YR 
220-257/ A LVAELGGGVA ANITSIAARF TKPVFPGETLSTVIWR 
266-277/ TEVAG SDGAEAR 
42 
6311 No positive Identification 
7104 No positive Identification 
7405 
§
 43566 
 
5.28 
 
35-59/ VLHDKF PDLNETKAFDQIDNAPEER 
62-92/ GITINIAHV EYQTDKRHYA HVDAPGHADY IK 
127-173/ QVGV PYILVALNKA DAVDDEELLELVEMEVRELL 
AAQEFDEDAP VVR 
185-225/ WVASV EELMNAVDESIPDPVRETDK PFLMPVEDVF 
TITGR 
236- 282/ GVINV NEEVEIVGIRPSTTKTTVTG VEMFRKLLDQ 
GQAGDNVGLL LR 
292-317/ GQVVTKPGTTTPHTEFEGQ VYILSK 
322-336/ HTPFFNNYR PQFYFR 
365-376/ LIQPVA MDEGLR 
296 40 61 
47948 
 
5.36 
 
1-11/ MADTDDTATL R 
57-70/ SSIT YIDGDAGILR 
73-82/ GYPIDQLA EKS 
113-122/ HTMLHEDL KR 
182-220/ SVGQPFLYP DNSLTLVENF LRLTFGFPAE 
PYQADPEVVR 
345-359/ ELEEAALTDDYFIER 
360-374/ LYPNVDFYTG LIYR 
392-400/ LPGWIAHWR 
414-431/ QIYTGY TERDYVTIDA R 
32 
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PREDICTED FUNCTION OF IDENTIFIED PROTEINS 
Predicted functions were assigned to the proteins identified from experiment 1 and 3 using the Tuberculist 
database (http://genolist.pasteur.fr/TubercuList) and then categorized according to their cellular processes 
(1). These processes include: (i) small molecule metabolism; (ii) cell processes; (iii) macro molecule 
metabolism and (iv) hypothetical proteins (Table 4.7). Proteins involved in small molecule metabolism 
could be further divided in the following processes: Energy metabolism (n=7); degradation (n=2); 
biosynthesis of cofactors, metabolic groups and carriers (n=2); lipid biosynthesis (n=1); central 
intermediate metabolism (n=1) or classified as purines, pyrimidines, necleosides and nucleotides (n=2). 
Macro molecule metabolism was further divided in two processes: Synthesis and modification of macro 
molecules (n=1) and degradation of macro molecules (n=1). Only one protein involved in cellular 
processes were identified. This protein functions as a chaperone or heat shock protein which prevents the 
misfolding of proteins and promotes the refolding and proper assembly of unfolded polypeptides 
generated under stress conditions. In total, thirteen proteins were classified as hypothetical proteins. 
48776 5.4 
 
83-97/ IAEQLEAQ ADVEAER 
119-127/LE LGHESVR 
221-233/ YLTVPAEDA TPR 
237-254/ LIERL VSGKVGAPTLEVLR 
333-372/ ADSTVNP VVVALLSHTVELLRGQAVEE AVLFLAEVAV 
AR 
23 
8104 23279 5.62 4-15/ VFLVDDH EVVRR 
43-56/VPAARPDVAVLDVR 
156-168/TLLGL LSEGLTNK 
198-209/ TQAAVFATELKR 
58 5 23 
8501 49208 5.53 2-31/ THYDVVVLG AGPGGYVAAI R 
56-64/ NAELVH IFTK 
68-85/ AFG ISGEVTFDYG IAYDR 
148-168/ LVPGTSLSANVVT YEEQILSR 
192-205/ NYGVDVTIVEFLPR 
439-448-/WD LTASELAR 
66 6 20 
8502 49208 5.53 2-35/ THYDVVVLG AGPGGYVAAI RAAQLGLSTA IVEPK 
55-64/ NAELVH IFTK 
148-168/ LVPGTSLSANVVT YEEQILSR 
192-220/ NYGVDVTIV EFLPRALPNE DADVSKEIEK 
252-298/DGVAQELKA EKVLQAIGFA PNVEGYGLDK 
AGVALTDRKA IGVDDYMR 
385-196/ AHGVGD PSGFVK 
429-438/ WD LTASELAR 
72 13 35 
9105 No positive Identification 
9106 14572 4.46 8-46/ FNH LVTVTDLETG DRAVCDRDQV AETIRAWFPD APLEVR 
123-136/ MIGLGGGS PAEDER 
56 4 38 
Legend to Table 4.6: 
* According to Mascot results, Protein MOWSE scores greater than 52 were considered as significant. 
§ Spots were found to be a mixture of two or more proteins, each described in a row of the table. 
Ψ Percentage of protein sequence covered with identified peptides 
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Table 4.7: Functions of proteins identified through mass spectrometry analysis and bioinformatics and 
literature searches.  
A. SMALL MOLECULE METABOLISM 
 Spot nr Exp 
nr 
#
 
Accession 
nr 
Gene Protein Protein Function 
* 
E
n
er
g
y
 M
et
a
b
o
li
sm
 
1203 1 Rv3029c fixA Electron transfer 
flavoprotein beta- 
subunit 
Transfers electrons to main respiratory 
chain via ETF-ubiquinone oxidoreductase 
(ETF dehydrogenase) 
5905, 
6901 
1 Rv1308 atpA ATP synthase alpha 
chain 
Alpha chain (Regulatory unit) of FOF1 
ATP synthase, which produces ATP from 
ADP in presence of proton gradient across 
membrane.  
6402 1 R1446c opcA Putative oxpp cycle 
protein 
May be involved in functional assembly of 
glucose 6-phosphate dehydrogenase 
8501 3 Rv0462 lpdC Dihydrolipoamide 
dehydrogenase lpd 
Component of the alpha-ketoacid 
dehydrogenase complex 
04 3 Rv0363c fba Fructose 
bisphosphate aldolase 
Involved in glycolysis (catalytic activity) 
7405 3 Rv0896 gltA Citrate synthase 
GltA2 
Involved in tricarboxylic acid cycle (Krebs 
cycle, catalytic activity) 
7405 3 RV1307 atpH ATP synthase delta 
chain ATPH 
FOF1 ATP synthase subunit delta. Either 
transmits conformational changes from 
CF(0) into CF(1) or is implicated in proton 
conduction 
D
eg
ra
d
a
ti
o
n
 4502, 
4102 
1 R1070c echA8 Enoyl-coA hydratase Could possibly oxidize fatty acids using 
specific components 
5601 1 R3255c manA Mannose-6-
phosphate isomerase 
Converts D-Mannose 6-Phosphate to D-
fructose 6-phosphate 
B
io
sy
n
th
es
is
 o
f 
co
fa
ct
o
rs
, 
m
et
a
b
o
li
c 
g
ro
u
p
s 
a
n
d
 
ca
rr
ie
rs
 
3001 1 Rv3841 bfrB Possible 
bacterioferritin 
Stores iron in a soluble, nontoxic, readily 
available form 
6401 1 Rv0562 grcC1 Polyprenyl-
diphospate synthase 
Possibly supplies polyprenyl diphosphate 
P
u
ri
n
es
, 
p
y
ri
m
in
d
in
es
, 
n
u
cl
eo
si
d
e
s 
a
n
d
 
n
u
cl
eo
ti
d
es
 
4103 1 Rv0733 adk Adenylate kinase Intracellular nucleotide metabolism. Acts 
as nucleoside mono-and di-phospate 
kinase in RNA and DNA biosynthesis 
5302 1 Rv0780 purC Phosphribosylaminoi
midazole- 
succinocarboxamide 
synthase 
Involved in de novo purine biosynthesis 
74 
 
L
ip
id
 
b
io
sy
n
th
es
is
 6301 1 Rv0503c cmaA2 Cyclopropane 
mycolic acid 
synthesis 
Essential for cyclopropanation function. 
Transfers methylene group from S-
adenosyl-L-methionine to cis double bond 
of unsaturated fatty acid chain, resulting in 
replacement of double bond with 
methylene bridge.  
C
en
tr
a
l 
In
te
rm
ed
ia
te
 
m
et
a
b
o
li
sm
 5203 3 Rv1611 trpC Indole-3-glycerol 
phosphate synthase 
trpC 
Involved in  tryptophan biosynthesis 
pathway (catalytic activity) 
B. MACRO MOLECULE METABLOLISM 
 Spot nr  Accession 
nr 
Gene Protein Protein Function 
S
y
n
th
es
is
 a
n
d
 
m
o
d
if
ic
a
ti
o
n
 o
f 
m
a
cr
o
m
o
le
cu
le
s 
8603 1 Rv0685 tuf Elongation factor TU 
TUF 
Promotes the GTP-Dependent binding of 
aminoacyl-tRNA to A-site of ribosomes 
during protein biosynthesis 7405 3 
6301 1 Rv2889c tsf Elongation factor TU 
TSF 
Associates with EF-TU.GDP complex and 
induces exchange of GDP to GTP, it 
remains bound to the aminoacyl-tRNA.EF-
TU.GTP complex up to GTP hydrolysis 
stage on the ribosome. 
D
eg
ra
d
a
ti
o
n
 o
f 
m
a
cr
o
m
o
le
cu
le
s 01, 
4108, 
5102 
3 Rv2460c clpP2 Endopeptidase Clp 
chain P2 
Cleaves peptides in various proteins in a 
process that requires ATP hydrolysis 
3107 3 Rv2110c prcB Proteasome beta 
subunit PrcB 
Protein degradation 
C. CELL PROCESSES 
 Spot nr Exp 
nr 
Accession 
nr 
Gene Protein Protein Function 
C
h
a
p
er
o
n
es
/ 
H
ea
t 
sh
o
ck
 5602, 
3101 
1 Rv0440 groEL
2 
Chaperonin 2 Prevents misfolding and promotes 
refolding and proper assembly of unfolded 
polypeptides generated under stress 
conditions 4608, 
5606 
3 
D. HYPOTHETICAL PROTEINS 
 Spot nr Exp 
nr 
Accession 
nr 
Gene Protein Protein Function 
3201 1 Rv3866   Unknown 
5202 1 R3389c   Unknown 
7404 1 Rv2629   Unknown 
3101 1 Rv0036c   Unknown 
7405 1 Rv2032   Unknown 
03 3 Rv3583c   Unknown 
4608 3 Rv3132c   Unknown 
5203 3 Rv0730   Unknown 
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6205 3 Rv0146   Unknown 
6205 3 Rv3389c   Unknown 
8104 3 Rv3133c   Unknown 
8502 3 Rv0642   Unknown 
9106 3 Rv1573   Unknown 
 
 
 
Two genes, atpA (Spots 5905 and 6901) and atpH (spot 7405) indentified from two independent 
experiments were selected as candidates for subsequent transcriptomic and genomic analysis. These genes 
encodes for components involved in the production of energy that is essential for functions that includes 
membrane mediated metabolic processes such as efflux pumps. It has been shown that efflux mechanims 
regulate the intracellular concentration of RIF (Phd thesis, Gail E. Louw, 2009). Thus subsequent analysis 
focused on these two genes, atpA and atpH. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legend to Table 4.7 
# Proteins identified in either experiment 1 or 3 
*  Protein function according to http://genolist.pasteur.fr/TubercuList and categorized according to (1). 
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4.2. TRANSCRIPTOMICS 
QRT-PCR was done to determine the expression levels of the two candidate genes in response to RIF. 
Both genes were significantly up regulated in both strains in the presence of RIF (Table 4.8; Figure 4.5). 
The atpA gene showed a 19.023 (p=0.001) and 11.633 (p=0.001) fold increase in the high RIF MIC strain 
(R451) and the intermediate RIF MIC strain (R439) respectively. Whereas the atpH gene showed a 7.554 
(p=0.001) and 10.251 (p=0.005) fold increase in the high MIC strain (R451) and intermediate MIC strain 
(R439) respectively. Figure 4.4 is an example of a standard curve essay done for the reference gene, 16S. 
For this assay a slope of -3.41 and coefficient correlation of -1 was achieved. 
 
 
 
 
 
 
Figure 4.4: Standard curve of reference gene, 16S.  
A) The calculated CT values were plotted against the log ng total cDNA of each starting quantity. 
Correlation coefficient (r) and slope values are indicated. Each sample was run in duplicate. 
B) The calculated CT values were plotted against measured Fluorescence (F1) 
C) Duplicate CT values for serial dilution of sample 
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Table 4.8: Differential gene expression profiles of candidate genes 
Strain 
atpA atpH 
Fold change * p-value ** Fold change * p-value ** 
R451 (high MIC) 19.023 0.001 7.554 0.001 
R439 (intermediate MIC) 11.633 0.001 
 
10.251 0.005 
 
 
 
 
 
 
 
 
 
 
Legend to Table 4.8: 
* Fold change after 24h exposure to 2μg/ml RIF 
** p-value ≤ 0.05 were considered as significant 
Figure 4.5: mRNA Expression levels of atpA and atpH in R439 (intermediate MIC strain) and R451 
(high MIC strains) when exposed to 2μg/ml RIF. 
78 
 
4.3. GENOMICS  
After screening 20 resistant and 15 susceptible clinical isolates from different strain families, no 
mutations could be found in either the coding regions of the genes (atpA or  atpH) or 90bp upstream from 
these genes.  However, sequencing revealed a synonymous polymorphism in the atpH gene at codon 91 
which was specific for the LCC isolates (both drug resistant and susceptible isolates).  It is therefore 
possible that this polymorphism can be used as a genetic marker for the LCC family. However, a larger 
study is needed to confirm this observation.  
Additional bioinformatic analysis revealed that the atpA and atpH genes encode for two of the eight 
subunits that forms part the F0F1 ATP synthase enzyme (Table 4.9 and Figure 4.6). These genes are two 
of the largest in the cluster and each encodes for a catalytic subunit of FOF1 ATP synthase. 
 
Table 4.9: Genes transcribing for the subunits of F0F1 ATP synthase 
Gene Accesion 
nr 
Protein Structural unit Coding region start 
site 
Coding region end 
site 
Size (bp) 
atpB Rv1304 Subunit A 
Membrane proton 
channel F0 
1460244 1460996 752 
atpE Rv1305 Subunit C 
Membrane proton 
channel F0 
1461045 1461290 245 
AtpF Rv1306 Subunit B 
Membrane proton 
channel 
1461321 1461836 515 
AtpH Rv1307 
Subunit 
delta 
Catalytic subunit 1461843 1463183 1340 
atpA Rv1308 
Subunit 
alpha 
Catalytic subunit 1463228 1464877 1649 
AtpG Rv1309 
Subunit 
gamma 
Regulatory subunit 1464884 1465801 917 
atpD Rv1310 Subunit beta Regulatory unit 1465841 1467301 1460 
atpC Rv1311 
Subunit 
epsilon 
Catalytic subunit 1467315 1467680 365 
 
 
5.  
 
Figure 4.6: Gene orientation of gene cluster transcribing for subunits of F0F1 ATP synthase  
* Nucleotide position of start and end site of gene cluster 
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SUMMARY OF RESULTS 
Two candidate genes for transcriptomic and genomic analysis were identified through two independent 
proteomic experiments. Figure 4.7 summarizes the findings of this study.   
 
 
6.  
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Figure 4.7: Summary of results from Proteomics. Coloured arrows indicate the differential 
expression of proteins in the presence of RIF.  
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CHAPTER 5 
DISCUSSION 
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This is the first study to demonstrate a proteomic response to RIF exposure in two RIF resistant clinical 
strains of M. tuberculosis which demonstrate different levels of RIF resistance despite having identical 
genetic backgrounds. Analysis of the 2D gels (visually inspected or by PD Quest software) showed that 
the abundance of membrane proteins increased in response to RIF. The PD Quest analytical method 
identified a total of 86 differentially expressed proteins in the high RIF resistant strain (R451).  In 
contrast, the intermediate level RIF resistant strain (R439) showed less modification of protein expression 
after RIF exposure, with a total of 53 proteins being differentially expressed. However, the relative 
abundance of proteins in the unexposed and RIF exposed  condition of the intermediate RIF resistant 
strain could not be accurately quantified by this software as has been previously described (7,15). 
Together these results suggest that the high level RIF resistant strain stimulates various different 
pathways in response to RIF exposure that might enable the strain to survive under higher concentrations 
of RIF.   
 
Mass spectrometry of the most highly up regulated membrane proteins, identified proteins involved in a 
wide spectrum of cellular processes (Energy metabolism, degradation, biosynthesis of cofactors, 
metabolic groups and carriers, lipid biosynthesis, central intermediate metabolism, synthesis and 
modification of macromolecules, chaperone/heat shock proteins). This demonstrates that RIF induces a 
stress response in M. tuberculosis strains which harbor an rpoB mutation. Of the 41 proteins identified, 7 
(17%) are annotated to be involved in different pathways which are essential for the production of energy. 
We hypothesize that the up regulation of ATP synthesis enzymes would be essential to support the energy 
requirements of active efflux which had been previously shown to be a mechanism regulating the 
intracellular concentration of RIF in these strains (PhD thesis, Gail E. Louw, 2009). Thus our subsequent 
analysis focused on two of the proteins involved in ATP synthesis, atpA and atpH. Both of these proteins 
were weakly present prior to exposure with RIF and their abundance increased significantly in response to 
RIF. Transcriptomic analysis confirmed that atpA and atpH were up regulated in the presence of RIF in 
both strains. However, up regulation of the atpA gene was more pronounced in the high level RIF 
resistant strain (R451) than the intermediate level RIF resistant strain (R439). In contrast, the atpH gene 
was equally up regulated in both strains in the presence of RIF. In order to explain the up regulation of the 
atpA and atpH, each gene and the associated up stream regulatory domains were sequenced. No mutations 
were observed in the ribosome binding sites, while a single synonymous nucleotide polymorphism was 
observed at codon 91 of the atpH gene in both drug resistant and drug susceptible isolates. Therefore, this 
nucleotide substitution can be classified as a polymorphism. In addition, this polymorphism was found to 
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be specific for the LCC family and can therefore be used as a valuable tool to identify outbreaks of the 
LCC family. These genomic markers can aid in the understanding of the evolution and epidemiology of 
M. tuberculsosis strain families (9,16).  
 
AtpA and atpH encode for two of the eight subunits that forms part of the final enzyme, F0F1 ATP 
Synthase (complex V), of the oxidative phosphorylation pathway (4).  Annotation of the H37Rv genome 
shows that these genes are adjacently located together with a further six genes (atpB, atpE, atpF, atpG, 
atpD, atpC) (http://genolist.pasteur.fr/TubercuList) suggesting a single operon regulated by a common 
operator and promoter. This is supported by recent studies which have shown that all 8 of these genes are 
essential for in vitro growth (13) and are down regulated at 24h and 96h of starvation (2),oxygen 
depletion, NO treatment and during different respiratory states in a murine model of infection (14). 
Recently it was revealed that two additional genes, Rv1303 and Rv1312 are part of the ATP synthase 
operon  (12). It was also shown that that the binding site of a transcriptional regulator, Rv1846c, is 
located in a region upstream of the rv1303–atpBEFHAGDC–rv1312 operon. This suggests that the gene 
expression of this operon is regulated by Rv1846c.  The primary function of F0F1 ATP synthase is to 
convert electrochemical potential energy of protons into chemical energy of ATP phosphoanhydride 
bonds (6). However, in some organisms the reverse reaction, the hydrolysis of ATP to ADP produces a 
trans membrane proton pump, is more important (8). Interestingly, one of the subunits of the F0F1 ATP 
synthase, AtpE, was identified as the drug target of a promising new drug for the treatment of TB (11). 
TMC207 (also known as R207910) is the lead compound of a series of recently discovered 
diarylquinolines  (1). Recent clinical studies confirmed that TMC207 is active in vitro against both drug 
susceptible and drug resistant isolates , thereby confirming the essentiality of this enzyme for bacterial 
growth (1,5). Subsequently, it was shown that TMC207 decreased the time to smear conversion of MDR-
TB cases when used in combination with 2
nd
 line anti-TB drugs (5).   
 
From these findings we proposed a model which might explain how M. tuberculosis RIF resistant strains 
have adapted to survive under high concentrations of RIF. In a drug sensitive strain, the hydrophobic RIF 
molecule enters the cell through passive diffusion through the membrane. It binds to the beta subunit of 
the RNA polymerase (rpoB), inhibiting RNA transcription, which results in cell death. Under these 
conditions a low level of expression of efflux pumps (PhD thesis, Gail E. Louw, 2009) and ATP synthase 
(This study) was observed. In a RIF resistant strain a mutation in the rpoB gene results in a 
conformational change in the rpoB protein, thereby altering the binding constant between RIF and the 
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rpoB protein.  Thus transcription can proceed and the cell will continue to grow and replicate.  Under 
these conditions we postulated that the accumulation of unbound RIF in the cell will stimulate a stress 
response which will lead to the up regulation of genes involved in detoxification. These up regulated 
genes include efflux pumps (PhD thesis, Gail E. Louw, 2009), ATP synthase (this study) and other 
metabolic enzymes (this study). In this model ATP synthase will serve as an energy source, driving 
metabolic processes, including membrane ABC transporters. ABC transporters utilize free energy from 
ATP hydrolysis to pump a variety of compounds, including antibiotics, out of the cell, thereby defining 
the MIC for RIF (3,10). This model may explain how the inclusion TMC207 in the MDR-TB treatment 
regimen improves smear conversion. We propose that the inhibition of efflux by the inhibition of ATP 
synthesis will lead to an accumulation of anti-TB drug within the cell. The high intracellular 
concentration of anti-TB drug will allow for more efficient binding of the drug to the target and cell 
death.    
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Figure 5.1: Proposed model for the survival of M. tuberculosis RIF resistant strains under high concentrations of RIF 
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CHAPTER 6 
CONCLUSION 
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This study highlights the importance of investigating the mechanisms underlying drug resistance in 
clinical isolates. The originality and novelty of this study further lies in the application of state-of-the-art 
technologies to test the hypothesis that RIF resistance develops through unique mechanisms in addition to 
the nsSNP in the rpoB gene. In this study a three pronged approach (proteomic, transcriptomic and 
genomic methods) was used to enhance the possibility of identifying mechanisms which could explain 
variation in the level of RIF resistance in two closely related clinical isolates which demonstrate identical 
genetic backgrounds according to standard markers. Using these approaches it was possible to show that 
RIF induced expression of a number of different membrane proteins in both clinical isolates. Furthermore, 
it was evident that there was a correlation between the number of proteins up regulated and the level of 
RIF resistance. Together these results suggest that different strains may use different strategies to survive 
the toxic nature of RIF.  
 
Many of the up regulated proteins were associated with metabolic processes, in particular, the 
identification of two proteins, AtpA and AtpH, which may form part of an operon encoding for the FoF1 
ATP synthase. The identification of these two proteins in two independent experiments indicates that 
increased expression of these genes is essential for the survival of the bacterium after RIF exposure. 
These results were confirmed by QRT-PCR. No mutations involved in the regulation of translation could 
be identified to explain differential expression of these genes.  
 
By combining these results with other observations from our laboratory it was possible to propose a 
model to explain at least one mechanism whereby the two clinical isolates were able to regulate the 
intracellular concentration of RIF. In this model we suggest that RIF induces a toxic response which leads 
to up regulation of expression of a number of genes including efflux pumps and F0F1 ATP synthase. We 
suggest that the F0F1 ATP synthase provides the energy requirement to enable active efflux, thereby 
regulating the intracellular concentration of RIF. Our results provide the first evidence to suggest that the 
evolution of RIF resistance is a dynamic process involving a cascade of adaptive events which leads to a 
bacterial growth state where hydrophobic compounds are actively extruded from the cell. This contrasts 
significantly from the present dogma which suggests that the evolution of RIF resistance involves only a 
single mutation which disrupts in the binding of RIF to rpoB. If our model is correct this could have 
significant implications for the treatment of RIF resistant strains with hydrophobic anti-TB drugs as prior 
exposure to RIF may “condition” the bacillus to extrude these compounds thereby reducing their 
88 
 
therapeutic effect. This may explain why the inclusion of the ATP synthase inhibitor TMC207 in the 
treatment regimen improved the rate of smear conversion in patients with drug resistant TB.  We propose 
that TMC207 blocked energy production thereby limiting active efflux leading to an increase in the 
intracellular concentration of anti-TB drugs with a corresponding increase in bactericidal activity.  
 
Future studies need to rigorously test the proposed hypothesis, to establish the mechanisms whereby the 
cell detects the toxic effect of RIF and to determine the cascade of regulatory events which lead to up 
regulation of F0F1 ATP synthase and numerous efflux pumps. 
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CHAPTER 7 
FUTURE STUDIES 
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The following future studies are needed to test our proposed model: 
 
1. Determine if the ATP synthase operon are encoded by a single polycistronic DNA. This could be 
done by PCR amplification of intragenic regions. 
2. Determine if there are any internal promoters inside the coding region. This could be done by 
cloning the intragenic region upstream of a reporter gene and then measuring expression of the 
reporter in M. smegmatis. 
3. Determine the location of the ATP synthase operon promoter region by cloning the region 
upstream of Rv1303 into a “promoter-trap” plasmid. 
4. Identify genes that may regulate the expression of the ATP synthase operon using saturating 
transposon mutagenesis. 
5. Use saturating transposon mutagenesis to identify genes which sense the toxic compound (i.e. RIF).  
6. Determine whether other hydrophobic anti-TB drugs are able to stimulate up regulation of the ATP 
synthase operon by QT-PCR. 
7. Determine whether exposure of a RIF resistant strain to RIF induces resistance to other 
hydrophobic anti-TB drugs. 
8. Determine the effect of TMC207 on the activity of ABC transporters in drug resistant isolates by 
measuring the MIC for RIF in the presence of TMC207.  
 
 
 
